U. S. Securities and Exchange Commission

Washington, D. C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2024

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission File No. 001-41375

 

ACTELIS NETWORKS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   52-2160309
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
I.D. No.)

 

4039 Clipper Court, Fremont, CA 94538

(Address of principal executive offices)

 

(510) 545-1045

Registrant’s telephone number, including area code:

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   ASNS   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: as of November 14, 2024, 6,253,715 shares of the Company’s common stock, par value $0.0001 per share were issued and outstanding.

 

 

 

 

 

 

ACTELIS NETWORKS, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2024

 

TABLE OF CONTENTS

 

    PAGE
PART I - FINANCIAL INFORMATION F-1
     
Item 1. Condensed Consolidated Interim Financial Statements (Unaudited) F-1
  Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 F-3
  Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 F-5
  Unaudited Condensed consolidated statements of redeemable convertible preferred stock, warrants to placement agent and Shareholders’ equity F-6
  Unaudited Condensed Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2024 and 2023 F-8
  Notes to Condensed Consolidated Interim Financial Statements F-10
Item 2. Management’s Discussion & Analysis of Financial Condition and Results of Operations 1
Item 3. Quantitative and Qualitative Disclosure About Market Risk 9
Item 4. Controls and Procedures 9
     
PART II - OTHER INFORMATION 11
     
Item 1. Legal Proceedings 11
Item 1A. Risk Factors 11
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 13
Item 3. Defaults Upon Senior Securities 13
Item 4. Mine Safety Disclosures 13
Item 5 Other information 13
Item 6. Exhibits 14
     
SIGNATURES 15

 

i

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

 

 

 

 

 

ACTELIS NETWORKS, INC.

QUARTERLY REPORT FOR THE PERIOD ENDED September 30, 2024

(Unaudited)

 

 

 

 

 

 

 

F-1

 

 

ACTELIS NETWORKS, INC.

QUARTERLY REPORT FOR THE PERIOD ENDED September 30, 2024

(Unaudited)

 

TABLE OF CONTENTS

 

  Page
Condensed consolidated financial statements (unaudited) – U.S. dollars in thousands:  
Condensed consolidated balance sheets F-3 - F-4
Condensed consolidated statements of comprehensive loss F-5
Condensed consolidated statements of mezzanine and Shareholders' equity F-6 - F-7
Condensed consolidated statements of cash flows F-8 - F-9
Notes to condensed consolidated financial statements F-10 - F-23

 

 

 

 

 

 

 

F-2

 

 

ACTELIS NETWORKS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(U. S. dollars in thousands)

 

   September 30,
2024
  

 

December 31,
2023

 
Assets        
CURRENT ASSETS:        
Cash and cash equivalents   2,241    620 
Short term deposits   
-
    197 
Restricted cash equivalents   300    1,565 
Trade receivables, net of allowance for credit losses of $168 as of September 30, 2024, and December 31, 2023.   1,828    664 
Inventories   2,372    2,526 
Prepaid expenses and other current assets, net of allowance for doubtful debts of $181 and $144 as of September 30, 2024, and December 31, 2023, respectively   481    340 
TOTAL CURRENT ASSETS   7,222    5,912 
           
NON-CURRENT ASSETS:          
Property and equipment, net   52    61 
Prepaid expenses   592    592 
Restricted cash and cash equivalents   
-
    3,330 
Restricted bank deposits   91    94 
Severance pay fund   200    238 
Operating lease right of use assets   515    918 
Long term deposits   78    78 
TOTAL NON-CURRENT ASSETS   1,528    5,311 
           
TOTAL ASSETS   8,750    11,223 
           

 

F-3

 

 

ACTELIS NETWORKS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

UNAUDITED

(U. S. dollars in thousands)

 

   September 30,
2024
   December 31,
2023
 
Liabilities, Mezzanine Equity and shareholders’ equity        
CURRENT LIABILITIES:        
Credit line   927    
-
 
Current maturities of long-term loans   
-
    1,335 
Trade payables   893    1,769 
Deferred revenues   277    389 
Employee and employee-related obligations   760    737 
Accrued royalties   1,033    1,062 
Current maturities of operating lease liabilities   450    498 
Other current liabilities   735    1,122 
TOTAL CURRENT LIABILITIES   5,075    6,912 
           
NON-CURRENT LIABILITIES:          
Long-term loan, net of current maturities   150    3,154 
Deferred revenues   160    71 
Operating lease liabilities   62    405 
Accrued severance   226    270 
Other long-term liabilities   16    23 
TOTAL NON-CURRENT LIABILITIES   614    3,923 
TOTAL LIABILITIES   5,689    10,835 
           
COMMITMENTS AND CONTINGENCIES (Note 10)   
    
 
           
MEZZANINE EQUITY          
Redeemable convertible preferred stock - $0.0001 par value, 10,000,000 authorized as of September 30, 2024, December 31, 2023. None issued and outstanding as of September 30, 2024, December 31, 2023.   
-
    
-
 
           
WARRANTS TO PLACEMENT AGENT (Note 7)   228    159 
           
SHAREHOLDERS' EQUITY :          
Common stock, $0.0001 par value: 30,000,000 shares authorized: 6,254,664 and 3,007,745 shares issued and outstanding as of September 30, 2024, and December 31, 2023, respectively.   1    1 
Non-voting common stock, $0.0001 par value: 2,803,774 shares authorized as of September 30, 2024, and December 31, 2023, None issued and outstanding as of September 30, 2024, and December 31, 2023.   
-
    
-
 
Additional paid-in capital   45,095    39,916 
Accumulated deficit   (42,263)   (39,688)
TOTAL SHAREHOLDERS’ EQUITY   2,833    229 
           
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY   8,750    11,223 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).

 

F-4

 

 

ACTELIS NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

(U. S. dollars in thousands)

 

   Nine months ended
September 30,
   Three months ended
September 30,
 
   2024   2023   2024   2023 
                 
REVENUES   6,698    4,589    2,541    845 
COST OF REVENUES   2,792    3,043    798    619 
GROSS PROFIT   3,906    1,546    1,743    226 
                     
OPERATING EXPENSES:                    
Research and development expenses   1,793    2,117    543    691 
Sales and marketing expenses   2,001    2,332    727    691 
General and administrative expenses   2,398    2,805    790    971 
Other income   (163)   
-
    
-
    
-
 
TOTAL OPERATING EXPENSES   6,029    7,254    2,060    2,353 
                     
OPERATING LOSS   (2,123)   (5,708)   (317)   (2,127)
Interest expense   (590)   (512)   (246)   (161)
Other Financial income, net   138    1,865    52    1,421 
NET COMPREHENSIVE LOSS FOR THE PERIOD   (2,575)   (4,355)   (511)   (867)
                     
Net loss per share attributable to common shareholders – basic and diluted  $(0.59)  $(1.93)  $(0.09)  $(0.32)
Weighted average number of common stocks used in computing net loss per share – basic and diluted   4,429,738    2,254,235    6,014,548    2,685,626 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).

 

F-5

 

 

ACTELIS NETWORKS, INC.

CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY (continued)

(UNAUDITED)

U.S. dollars in thousands (except number of shares)

 

   Redeemable Convertible Preferred Stock   Warrants To Placement Agent   Common Stock   Non-voting
Common Stock
   Additional       Total 
Nine Months Ended  Amount   Amount   Number of shares   Amount   Number of shares   Amount   paid-in capital   Accumulated deficit   shareholders' equity 
BALANCE AS OF JANUARY 1, 2023          -    
-
    1,737,986        1        -        -    36,666    (33,402)   3,265 
Share based compensation   -    -    -    -    -    -    298    -    298 
Repurchase of common stock   -    -    (7,920)   *    -    -    (50)   -    (50)
Issuance of common stock and pre-funded warrants upon private placement, net of underwriting commissions and other offering costs   -    104    190,000    *    -    -    1,356    -    1,356 
Exercise of options into common stock   -    -    19,443    *    -    -    10    -    10 
Exercise of pre-funded warrants into common stock   -    -    754,670    *    -    -    -    -    * 
Reclassification of warrants from liabilities to equity   -    -    -    -    -    -    314    -    314 
Net comprehensive loss for the period   -    -    -    -    -    -    -    (4,355)   (4,355)
BALANCE AS OF SEPTEMBER 30, 2023   -    104    2,694,179    1    -    -    38,594    (37,757)   838 
                                              
BALANCE AS OF JANUARY 1, 2024   -    159    3,007,745    1    -    -    39,916    (39,688)   229 
Share based compensation           -    -    -    -    259         259 
Vesting of RSUs   
-
    
 -
    28,228    *     -     -    *     -    - 
Issuance of common stock, net of offering costs (note 7f)   -     -    227,939    *     -    
 -
    316    -    316 
Exercise of options into common stock   -    -    21,225    *     -    
 -
    32     -    32 
Warrant to lender   -    
-
    -    
-
    -    
-
    61    
-
    61 
Exercise of Pre funded warrants into common stock (Note 7b)    -     -    970,187    *     -    
 -
          -    * 
Warrant inducement agreement, net of offering costs (Note 7e)    -    27    999,670    *     -    
 -
    1,951     -    1,951 
Warrant inducement agreement, net of offering costs (Note 7d)   -    42    999,670    *     -    
 -
    2,560     -    2,560 
Net comprehensive loss for the period                  
 
     -    
 -
    
 
    (2,575)   (2,575)
BALANCE AS OF SEPTEMBER 30, 2024   -    228    6,254,664    1    -    -    45,095    (42,263)   2,833 

 

*Represents an amount less than $1 thousand.

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited)

 

F-6

 

 

ACTELIS NETWORKS, INC.

CONSOLIDATED STATEMENTS OF MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY (continued)

(UNAUDITED)

U.S. dollars in thousands (except number of shares)

 

   Redeemable Convertible Preferred Stock   Warrants To Placement Agent   Common Stock   Non-voting
Common Stock
   Additional       Total 
Three Months Ended  Amount   Amount   Number of shares   Amount   Number of shares   Amount   paid-in capital   Accumulated deficit   shareholders' equity 
BALANCE AS OF JUNE 30, 2023         -    104    1,930,718         1          -        -    38,174    (36,890)   1,285 
Share based compensation   -    -    -    -    -    -    106    -    106 
Exercise of options into common stock   -    -    8,791    *    -    -    *    -    * 
Exercise of pre-funded warrants into common stock   -    -    754,670    -    -    -    *    -    * 
Reclassification of warrants from liabilities to equity   -    -    -    -    -    -    314    -    314 
Net comprehensive loss for the period   -    -    -    -    -    -    -    (867)   (867)
BALANCE AS OF SEPTEMBER 30, 2023   -    104    2,694,179    1    -    -    38,594    (37,757)   838 
                                              
BALANCE AS OF JUNE 30, 2024   -    201    5,017,322    1    -    -    42,687    (41,752)   936 
Share based compensation   -    -               -     -    80         80 
Vesting of RSUs   -    -    9,733    *     -     -    -    
 
    - 
Warrant to lender   -    
-
    -    
-
    -    -    61         61 
Warrant inducement agreement, net of offering costs (Note 7e)   -    27    999,670    *     -     -    1,951         1,951 
Issuance of common stock, net of offering costs (note 7d)   -    -    227,939    *     -     -    316         316 
Net comprehensive loss for the period   -    -               -     -         (511)   (511)
BALANCE AS OF SEPTEMBER 30, 2024   -    228    6,254,664    1     -     -    45,095    (42,263)   2,833 

 

*Represents an amount less than $1 thousand.

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).

 

F-7

 

 

ACTELIS NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   Nine months ended
September 30,
 
   2024   2023 
   U.S. dollars in thousands 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss for the period   (2,575)   (4,355)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   11    20 
Changes in fair value related to warrants to lenders and investors   
-
    (1,658)
Warrant issuance costs   
-
    223 
Inventories write-downs   39    132 
Interest expenses   (56)   
-
 
Exchange rate differences   (58)   (365)
Share-based compensation   259    298 
Financial income from short and long term bank deposit   (11)   (78)
Changes in operating assets and liabilities:          
Trade receivables   (1,164)   2,319 
Net change in operating lease assets and liabilities   12    25 
Inventories   115    (1,651)
Prepaid expenses and other current assets   (140)   62 
Long term prepaid expenses   
-
    (100)
Trade payables   (875)   411 
Deferred revenues   (23)   (262)
Other current liabilities   (350)   (185)
Other long-term liabilities   35    (30)
Net cash used in operating activities   (4,781)   (5,194)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Short term deposits   198    1,363 
Long term Restricted bank deposits   
-
    75 
Long term deposits   
-
    (2)
Purchase of property and equipment   (1)   (6)
Net cash provided by investing activities   197    1,430 
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of options   32    10 
Proceeds from issuance of common stocks, pre-funded warrants and warrants   *    3,500 
Proceeds from issuance common stock, net of offering costs   316    
-
 
Proceeds from credit lines with bank, net   927    
-
 
Proceeds from Warrant inducement agreement   5,248    
 
 
Underwriting discounts and commissions and other offering costs   (668)   (291)
Early repayment of long-term loan   (4,038)   
 
 
Repayment of long-term loan   (193)   (583)
Repurchase of common stock   
-
    (50)
Net cash provided by financing activities   1,624    2,586 
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS   (14)   (12)
           
DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS   (2,974)   (1,190)
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD   5,515    4,279 
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD   2,541    3,089 

 

*Represents an amount less than $1 thousand.

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).

 

F-8

 

 

ACTELIS NETWORKS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(UNAUDITED)

 

   September 30 
   2024   2023 
   U.S. dollars in thousands 
         
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH:        
Cash and cash equivalents   2,241    682 
Restricted cash equivalents, current   300    
-
 
Restricted cash and cash equivalents, non-current   
-
    2,407 
Total cash, cash equivalents and restricted cash   2,541    3,089 

 

   Nine months ended
September 30,
 
   2024   2023 
   U.S. dollars in thousands 
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION:        
Cash paid for interest  $576   $512 
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:          
Issuance costs of common stock, pre-funded warrants and warrants   
-
   $104 
           
Reclassification of warrants from liability to equity upon amendment to private placement agreement  $
-
   $314 
Issuance costs of the Warrant inducement agreement  $2,651    
-
 
Warrant to lender  $61    
-
 

 

The accompanying notes are an integral part of these condensed consolidated financial statements (Unaudited).

 

F-9

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 1 – GENERAL:

 

a.Actelis Networks, Inc. (hereafter -the Company) was established in 1998, under the laws of the state of Delaware. The Company has a wholly-owned subsidiary in Israel, Actelis Networks Israel Ltd. (hereafter – the Subsidiary). The Company is engaged in the design, development, manufacturing, and marketing of cyber hardened, hybrid fiber, networking solutions for IoT and Telecommunication governmental agencies and companies. The Company’s customers include governmental agencies, providers of telecommunication services, enterprises as well as resellers of the Company’s products. On May 12, 2022, the Company accepted a notification of effectiveness from the SEC, and on May 17, 2022, completed its IPO. The Company’s Common Stock is listed on the NASDAQ.

 

b.The Company has incurred significant losses and negative cash flows from operations. Net loss was $2,575 and $4,355 for the nine months ended September 30, 2024, and September 30, 2023, respectively. During the nine months ended September 30, 2024, and September 30, 2023, the Company had negative cash flows from operations of $4,781 and $5,194, respectively. As of September 30, 2024, the Company’s accumulated deficit was $42,263. The Company has funded its operations to date through equity and debt financing and has cash on hand (including restricted cash equivalents) of $2,541 restricted bank deposits of $91 as of September 30, 2024. The Company monitors its cash flow projections on a current basis and takes active measures to obtain the funding it requires to continue its operations. However, these cash flow projections are subject to various uncertainties concerning their fulfilment such as the ability to increase revenues by attracting and expanding its customer base or reducing cost structure. If the Company is not successful in generating sufficient cash flow or completing additional financing, including debt refinancing which shall release restricted cash, then it will need to execute a new cost reduction plan in addition to previous cost reduction plans that were executed so far. The Company’s transition to profitable operations is dependent on generating a level of revenue adequate to support its cost structure. The Company expects to fund operations using cash on hand, through operational cash flows and raising additional proceeds. There are no assurances, however, that the Company will be able to generate the revenue necessary to support its cost structure or that it will be successful in obtaining the level of financing necessary for its operations. Management has evaluated the significance of these conditions and has determined that the Company does not have sufficient resources to meet its operating obligations for at least one year from the issuance date of these condensed consolidated financial statements. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

 

c.On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern and Central Israel, to which the Israel Defense Forces have responded. In addition, both Hezbollah and the Houthi movement have attacked military and civilian targets in Northern Israel, to which Israel has responded, including through increased air and ground operations in Lebanon. In addition, the Houthi movement has attacked international shipping lanes in the red sea. Further, on April 2024, and on October 2024, Iran launched a series of drone and missile strikes against Israel, to which Israel has responded. To date our operations and financial results have not been materially affected. The Company continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments impacting its financial statements as appropriate, while supporting the safety and well-being of its employees. It is currently not possible to predict the effects of such conflicts and its impact on the Company’s business, operations or financial conditions. We continue to monitor political and military developments closely and examine the consequences for our business, results of operations and financial condition.

 

F-10

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 1 – GENERAL: (continued):

 

On November 21, 2023 we applied for an Israeli government grant associated with the Swords of Iron war declared by the State of Israel following the October 7, 2023 attack by Hamas.

 

The Company was found eligible and received an amount of $163 which was recognized as other income during the second quarter in 2024. The grant is not repayable.

 

d.On August 25, 2023, the Company received a notification letter from the Nasdaq Staff indicating that the company was not in compliance with Nasdaq Listing Rule 5550(b)(1) due to the company's failure to meet the Minimum Shareholders’ Equity Requirement or any alternatives to such requirement. In order to maintain listing on the Nasdaq Capital Market, the company has submitted a plan of compliance addressing how we intended to regain compliance. The company had until February 21, 2024 to evidence compliance with the Minimum Shareholders’ Equity Requirement.

 

On March 27, 2024, the Company received a delist determination letter (the “Delist Letter”) from the Staff advising the Company that the Staff had determined to delist the Company’s securities from Nasdaq due to its non-compliance with the Equity Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel. Following the hearing, on June 10, 2024, the Panel granted the Company’s request for continued listing subject to the Company evidencing compliance with the Minimum Shareholders’ Equity Requirement by August 30, 2024.

 

On August 27, 2024, the Company received formal written notice from the Nasdaq Staff confirming that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), the Company will remain subject to Panel monitor for equity compliance through August 27, 2025.

 

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

 

a.Basis of presentation

 

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Article 10 of the Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States (“U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the 2024 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation.

 

b.Use of estimates in preparation of financial statements

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

 

F-11

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued):

 

c.Fair value of financial instruments

 

Fair value measurements are classified and disclosed in one of the following three categories:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company measured the fair value of the warrants it issued (see note 5) based on Level 3 inputs, and the warrants liability amounted to $8 as September 30, 2024 and December 31, 2023, are presented in the Other current liabilities in the accompanying condensed consolidated balance sheets.

 

As of September 30, 2024, and December 31, 2023, the fair values of the Company’s cash and cash equivalents, restricted cash and cash equivalents, short and long-term deposits, trade receivables, trade payables, long-term loan, restricted bank deposits, Severance pay fund and other current assets approximated the carrying values of these instruments presented in the Company’s condensed consolidated balance sheets because of their nature.

 

d.Concentration of risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.

 

Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.

 

The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.

 

Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.

 

Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.

 

F-12

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued):

 

The Company has customers balances representing 10% or more of Trade receivables as follows:

  

 

1) 

Customer A represented 0% and 30% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

 

 

2) Customer B represented 4.5 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

 

3)

Customer C represented0 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

4)Customer D represented 38% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

5)Customer E represented 21.4% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

The Company does not see any credit risk regarding the major trade receivable balance.

 

New Accounting Pronouncements

 

Accounting Pronouncements effective in future periods

 

In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

 

NOTE 3 – INVENTORIES:

 

   September 30,
2024
   December 31,
2023
 
Raw materials   1,344    757 
Finished goods   1,028    1,769 
    2,372    2,526 

 

Inventory write-downs amounted to $39 and $132 during the nine months ended September 30, 2024, and 2023, respectively and $14 and $35 during the three months ended September 30 2024 and 2023, respectively. Inventories write-downs are recorded in cost of revenues.

 

NOTE 4 – LOANS:

 

a.As a result of the COVID pandemic, the US and Israeli governments offered different programs of financial aid. The Company participated in the following programs:

 

On July 1, 2020, the Company received Economic Injury Disaster Loan (the “EIDL Loan”) from an American Bank under the Small Business Administration COVID19 Program in the total of $150. The loan matures in June, 2050 and bears interest of 3.75% per annum, payable monthly commencing on January 1, 2023, unless forgiven per program regulations. As of September 30, 2024, the total loan balance outstanding was $150

 

F-13

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 4 – LOANS: (continued):

 

b.On December 9, 2020, the Company signed a new loan agreement with an Israeli based financial institution (“Migdalor”) for a loan of up to 20 million NIS ("New Israeli Shekel") (an amount of $6,000). The Company received $3,000 on December 2020, and additional $2,000 in January 2021. The loan bears interest of 9.6% per annum. The interest shall first be paid in 12 payments starting February 1, 2021. Starting February 1, 2022, the loan principal and interest shall be repaid in 72 equal payments, plus a one-time interest payment after the 36th month.

 

As part of the loan agreement, the Company issued the New Lender warrants to acquire common stock in the amount of $1,500.

 

In November 2021, the Company received additional funding in the amount of $1,000 from Migdalor. The loan bears interest of 9.6% per annum. Starting February 1, 2022, the loan principal and interest shall be repaid in 72 equal monthly payments, plus a onetime interest payment after the 24th month. The Company increased the value of the warrant issued to Migdalor to $1,800. Upon the consummation of the IPO, the Company converted all the above outstanding warrants issued to Migdalor into the Company’s common stock based on the contractual terms and conditions of the related warrant agreements.

 

The loan covenants (the “covenants”) include a debt to EBITDA minimum ratio or a coverage ratio of the loan by current assets.

   

On December 21, 2022, pursuant to the terms of the loan agreement, the Company deposited $2,000   to a Company-owned interest-bearing bank account, or the “designated account” (as defined in the agreement), to satisfy the required obligation associated with the loan agreement. An additional $2,000 was deposited in the designated account during the year ended December 31, 2023, which was classified in Restricted cash equivalents in the condensed Consolidated Balance Sheet.

 

As of September 30, 2024, the Company was in compliance with the covenants   of the Migdalor loan.

 

In February 2024, the Company performed a partial early repayment of Migdalor Loan in the amount of 2 million NIS (approximately $550). During April and May 2024, the Company made an additional partial early repayment of Migdalor loan in the amount of 10.9 million NIS approximately $2,933). In May 2024, the Company signed an amendment to the agreement with Migdalor, pursuant to which the remaining $470 of the one-time interest payment which was originally due in January 2024 to Migdalor will be paid in 12 equal monthly payments bearing 9.6% interest from February 2024 till February 2025. In addition, the Company is obligated to issue Migdalor warrants to acquire common stock for up to $150 subject to the agreed upon formula. The Company has a paid, during July 2024, a total amount of $196 (for the periods from February to June) of the one-time interest payment.

 

In July 2024, the company repaid the remaining loan balance to Migdalor, totaling 1.16 million ILS (approximately 0.3$ million )

 

As of September 30, 2024, the total outstanding of the one-time interest payment was 0.7 million NIS (approximately $0.2 million).

 

c.On January 15, 2024, the Subsidiary entered into a credit agreement with Bank Mizrahi-Tefahot. The Credit Agreement provides for a $1,500 credit facility available to be used by the Subsidiary (“New Credit Line”). Under the New Credit Line, which will be secured by the Subsidiary’s customer receivables, the Subsidiary will pay an annual fixed interest at a Federal SOFR rate plus 5.5% on any amount withdrawn under the New Credit Line. The New Credit Line, at an annual fixed interest rate of 1.5% for unused credit amount, expires on December 27, 2024, subject to extension.

 

Under the Credit Agreement, the Company is permitted to draw upon the New Credit Line for customer invoices that meet the following conditions:

 

(a)Throughout the duration of the New Credit Line, the Company may present customer receivables and receive credit financing that does not exceed 80% of the aggregate amount of the open customer invoices securing the New Credit Facility; The credit financing is to be repaid within 90 days.

 

(b)Customer invoices are payable within 90 days from the date of the Company’s monthly report to the Lender; and

 

(c)No single customer of the Company may account for open customer invoices securing over 30% of the total borrowed amount under the New Credit Line.

 

The Credit Line balance drawn will be examined every month and adjusted up to every three months and Repayment of the Credit Line will be made up to every three months subject to the expiration of the financing period for the invoices that were financed. The Company may refinance newly issued invoices at any time up to the Credit Line limit and subject to the terms of the Credit Line.

 

As of September 30, 2024, the Subsidiary used $0.9 million of the credit line. 

F-14

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 5 – WARRANTS:

 

The company has several types of warrants. The warrants classified as liability are presented in this note, and the equity warrants are presented under note 7. 

 

a.On August 24, 2016, the Company issued warrants to Comerica Bank (“Comerica”) for the purchase of 7,305 shares of the Company’s Series B Redeemable Preferred Stock at an exercise price of $10.2672 per share contemporaneously with obtaining a loan from Comerica which was fully repaid in 2018 (the “Comerica Warrants”). The Comerica Warrants are exercisable at any time during the contract period which ends on August 24, 2026.

 

Additionally, in connection with the consummation of the IPO which occurred in May 2022, and the change of the type of the stock from redeemable preferred stock to common stock at conversion, the Company reassessed the Comerica Warrants. As part of the contractual terms and conditions of Comerica’s Warrants, a portion of the warrants are exercisable, as of the IPO date, into the Company’s common stock.

 

The Company has evaluated whether the Comerica Warrants are still classified as liabilities and concluded that due to a change-of-control provision which may affect the exercise price or entitle Comerica to demand cash, instead of shares, to settle the warrants, Comerica’s Warrants will continue to be classified as liabilities and will be exercisable into the Company’s common shares. The Comerica Warrants are still outstanding as of September 30, 2024.

 

b.On May 8, 2023, the Company completed a fund-raising round. Upon the consummation of the Offering and pursuant to an agreement entered into with the Holder and the underwriter, the Company issued warrants to purchase shares of Common Stock. Such warrants were classified as liabilities based on the terms of the underlying agreement. On September 30, 2023, these warrants were reclassified to equity due to an amendment to the warrants’ agreements (for further details see also Note 7b). On June 6, 2024, these warrants were exercised pursuant to the inducement agreement, as described in notes 7d below.

 

NOTE 6 – COMMITMENTS AND CONTINGENCIES:

 

The Company is obligated to repay certain research and development grants received from the Government of Israel in the form of a royalty rate on future sales of products derived from the funded research and development activities. The aggregate amount of royalties to be paid is determined based on 100% of the total grants received for qualified projects plus interest. The Company may be required to pay royalties based on previous years funding in periods after September 30, 2024, for the future sale of product that includes technology developed and funded with these research and development grants received to date.

 

As of September 30, 2024, the Company had received approximately $14,300 (approximately $15,830 including interest) and repaid approximately $10,518 in such grants.

 

As of September 30, 2024, and December 31, 2023, the Company had a liability to pay royalties in the amount of approximately $1,033 thousands and $1,062 thousands respectively.

 

F-15

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY:

 

a.During January and February 2023, the Company purchased 7,920 shares of its common stock, for a total price of $50. (Total of 10,690 common stock are held by the company as treasury shares).

 

b.Offering of common stocks and warrants May 2023:

 

On May 8, 2023, the Company completed a fund-raising round in a total gross amount of $3,500 pursuant to which the Company agreed to issue and sell to Armistice Capital Master Fund Ltd. (the “Holder”) in a private placement (the “Offering”):

 

1.190,000 shares of the Company’s common stock, $0.0001 par value;

 

2.754,670 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 754,670 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement. The warrants were classified as equity pursuant to ASC 815-40. During July and August 2023, the Holder elected to exercise 754,670 of the pre-funded warrant. The total exercise price in the amount of $0.0755 was paid in cash.

 

3.warrants to purchase up to 944,670 shares of Common Stock (“Common Warrants”) for an exercise price of $3.58 which are exercisable (physically or upon occurrence of certain events on net-cash basis at the Holder’s discretion) immediately upon their issuance until November 8, 2028. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

The Company determined that the Common Warrants are not indexed to the Company’s own stock and therefore are precluded from equity classification. The Common Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized as financial income or expense as change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of comprehensive loss.

 

The Common Warrants were recorded at fair value on May 8, 2023, at $1,972 and were classified as a long-term liability on the Condensed Consolidated Balance Sheet, and the residual value allocated to the common stock and pre-funded warrants which were classified as equity.

 

On September 30, 2023, the Company and the Holder entered into a Common warrants amendment agreement (the “Amendment”) to amend the Common warrants to purchase up to 944,670 shares of the Company’s common stock, par value $0.0001 issued to the Holder. The Amendment made certain adjustments to the definition of a “Fundamental Transaction” in Common Warrant agreement. Additionally, the Amendment increased the number of Common Warrants to include an additional 55,000 Common warrants and changed the exercise price of the Common Warrants to $2.75.

 

The Company reclassified the Common warrants as equity based on the guidance provided under ASC 815-40, due to the adjustments stated in the amendment. As of the date of the amendment of the Common warrants, the fair value of the warrants was estimated at $314.

 

F-16

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY: (continued):

 

b.Offering of common stocks and warrants May 2023: (continued)

 

Offering Costs related to May 2023 fund-raising round

 

Upon the consummation of the Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $291. The Company has also granted to the Underwriter upon the consummation of the Offering, warrants to purchase up to 66,127 of the Company’s common stocks which carry the same terms as the common stock warrants, except for the exercise price which reflect 125% of the share price in the Offering ($4.6313). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $104.

 

c.Offering of common stocks and warrants December 2023

 

On December 20, 2023, the Company completed a fund-raising round in a total gross amount of $1,500 pursuant to which the Company agreed to issue and sell to the Holder in December’s private placement (the “Second Offering”):

 

1)301,000 shares of the Company’s common stock, $0.0001 par value;

 

2)970,187 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 970,187 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on a net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement. During June 2024, the Holder elected to exercise 970,187 of the pre-funded warrant. The total exercise price in the amount of $0.097 was paid in cash.

 

d.Warrant Inducement Agreement June 2024:

 

3)warrants to purchase up to 1,271,187 shares of Common Stock (“Common Warrants”) for an exercise price of $1.18 which are exercisable (physically or upon occurrence of certain events on a net-cash basis at the Holder’s discretion) immediately upon their issuance until June 20, 2029. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement). 

 

In connection with the Second Offering, the Company also has agreed to amend the existing warrants to purchase up to an aggregate of 999,670 shares of the Company’s common stock that were previously issued in May 2023 (and amended in September 2023) at an exercise price of $2.75 per share, such that effective on the date of shareholder approval to amend the warrants, the amended warrants will have a reduced exercise price of $1.18 per share. In the event that the Shareholder Approval is not obtained, the warrant amendment shall be null and void and the provisions of the existing warrants shall remain unchanged. The shareholder approval was not obtained until June 5, 2024, when the Company entered into a warrant inducement agreement with the Holder. See note 7(d) for further details.

 

The common stock, pre-funded warrants and the warrants were classified as equity pursuant to ASC 815-40.

 

F-17

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY: (continued):

 

d.Warrant Inducement Agreement June 2024: (continued)

 

Offering Costs related to December 2023 fund-raising

 

Upon the consummation of the Second Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $129. The Company has also granted to the Underwriter upon the consummation of the Second Offering, warrants to purchase up to 88,983 of the Company’s common stocks which carry the same terms as the common stock warrants described above (Note 7b.), except for the exercise price which reflect 125% of the share price in the Second Offering ($1.475). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $55. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 57%, a risk-free rate of 3.86%, a contractual term of 5.5 years and a stock price at the issuance date of 1.18.

 

The total Second Offering costs in the amount of $230 was recognized in equity.

 

On June 5, 2024, the Company entered into a warrant inducement agreement with the Holder (as defined in Note 7b above) regarding the Common Warrants to purchase up to an aggregate of 999,670 shared of the Company’s common stock originally issued on May 8, 2023 at an exercise price of $2.75 per share (the “Existing Warrants”).

 

Pursuant to the inducement agreement, the Holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.75 per share in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “June Warrants”) for an exercise price of 2.00$ at a 1:1 exchange ratio.

 

As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.

 

The June Warrants will be exercisable immediately upon issuance, half of which with a term of 5.5 years (the “5.5 Years June Warrants”), and the remaining with a term of 2 years (the “2 Years June Warrants”) (physically or upon occurrence of certain events on a cashless basis at the Holder’s discretion). Their exercise price and the number of shares issuable upon exercise is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

Pursuant to the inducement agreement the Holder exercised the Existing Warrants for a total gross cash amount of approximately $2,999, before deducting offering costs.

 

As of the issuance date of the June Warrants, the fair value of the warrants was estimated at $1,451. The Company valuation was based using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:

 

   5.5 Years
June
Warrants
   2 Years
June
Warrants
 
Term   5.5 years    2 years 
Expected volatility   44.77%   44.77%
Risk-free rate   3.95%   4.28%
Stock price  $1.97   $1.97 

 

In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the Induced Warrants was accounted for as an additional equity issuance cost for the warrant inducement, which was recorded to additional paid-in capital. On June 30, 2024, the Company entered into a warrant inducement agreement with the Holder. See note 7(e) for further details.

 

F-18

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY: (continued):

 

d.Warrant Inducement Agreement June 2024: (continued)

 

Offering Costs related to warrant inducement agreement June 2024:

 

Upon the consummation of the to the warrant inducement agreement and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of 331$ and has paid other related issuance cost amounting to approximately $66. The Company has also granted to the Underwriter upon the consummation of the warrant inducement, warrants to purchase up to 69,977 of the Company’s common stocks which carry the same terms as the June Warrants described above, except for the exercise price which reflect 125% of the reduced exercise price of the Existing Warrants ($3.4375). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $42. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 44.77% a risk-free rate of 3.95% contractual term of 5.5 years, and a stock price at the issuance date of $1.97.

 

The total offering costs (including the inducement effects) in the amount of approximately $1,890 was recognized in equity.

 

e.Warrant Inducement Agreement July 2024:

 

On June 30, 2024, the Company entered into a warrant inducement agreement with Holder (as defined in Note 7b above), to purchase up to an aggregate of 999,670 shares of the 2 Years June Warrants, originally issued on June 6, 2024 at an exercise price of $2.00 per share (the “2 Years June Warrants”). The closing date of the June 30, 2024 Inducement Letter Agreement was on July 2, 2024.

 

Pursuant to the inducement agreement, the holder agreed to exercise for cash the 2 Years June Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.00 per share, in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “July Warrants”), for an exercise price of $1.75 at a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $250.

 

The July Warrants will be exercisable immediately upon issuance, with a term of 2 years.

 

Their exercise price and the number of shares issuable upon exercise is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

Pursuant to the inducement agreement the Holder exercised the 2 Years June Warrants for a total gross cash amount of approximately $2,249, before deducting offering costs.

 

As of the issuance date of the July Warrants, the fair value of the warrants was estimated at $1,131. The Company valuation was based using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:

 

   2 Years
June
Warrants
 
Term   2 years 
Expected volatility   61.60%
Risk-free rate   4.28%
Stock price  $1.65 

 

F-19

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY: (continued):

 

e.Warrant Inducement Agreement July 2024: (continued)

 

In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the induced warrants was accounted for as an additional equity issuance cost for the warrant inducement, which was recorded to additional paid-in capital. These warrants have not been exercised as of September 30, 2024.

 

Offering Costs related to warrant inducement agreement July 2024:

 

Upon the consummation of the to the warrant inducement agreement and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $271. The Company has also granted to the Underwriter upon the consummation of the warrant inducement, warrants to purchase up to 69,977 of the Company’s common stocks which carry the same terms as the July Warrants described above, except for the exercise price which reflect 125% of the reduced exercise price of the June Warrants ($2.50). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $27. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 61.60% a risk-free rate of 3.86% contractual term of 2 years, respectively, and a stock price at the issuance date of 1.65$.

 

The total offering costs (including the inducement effects) in the amount of approximately $1,429 was recognized in equity.

 

Total outstanding warrants as of 30 September,2024, are as follow:

 

    Number of warrants   Exercise
price
   Period left in years 
Warrants May 2023    66,127    $4.625    4.15 
Warrants December 2023    1,360,170    $1.18 - $1.47    4.75 

Warrants June 2024

    1,069,647    $2.0 – $3.43    5.25 
Warrants July 2024    2,069,317    $2.5-$1.75    2.0 
Other    36,792    $10.27 - $50    1.752.65 
Outstanding as of September 30, 2024    4,602,053           

 

f.At the Market Offering Agreement:

 

On September 18, 2024, the Company entered into At the Market Offering Agreement (the “ATM Agreement”), with H.C. Wainwright & Co. (“Wainwright”), as sales agent, pursuant to which the Company may issue and sell shares of its common stock, from time to time, through Wainwright.

 

Under the ATM Agreement, Wainwright may sell shares in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, as amended, or in any other method permitted by law, including in privately negotiated transactions.

 

The Company or Wainwright may suspend or terminate the ATM Agreement upon notice to the other party and subject to other conditions.

 

The Company will pay Wainwright a commission of 3.0% of the gross sales price of any common stock sold under the ATM Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company will also reimburse Wainwright for certain specified expenses.

 

On September 25, 2024, in connection with the execution of the ATM Agreement, the Company filed with the SEC a prospectus supplement (the “Prospectus Supplement”) to the base prospectus contained in the 2024 Shelf Registration Statement, which Prospectus Supplement related to the offering of up to $3.4 million of shares of the Company’s common stock under the ATM Agreement.

 

Subsequent to entering into the ATM Agreement, the Company issued and sold 227,939 shares of common stock for gross proceeds of approximately $328.

 

F-20

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 7 – SHAREHOLDERS’ EQUITY: (continued):

 

g.Share-based compensation:

 

1)A summary of the Company's share options, granted to employees, directors, under option plans is as follows:

 

    Number of options   Weighted Average Exercise
Price
   Weighted Average Remaining Contractual Life 
Outstanding – January 1, 2024    87,764   $3.63    4.11 
Granted    
-
    
-
    - 
Exercised    (21,225)  $3.37                  - 
Forfeited    (1,159)  $16.5    - 
                 
Outstanding - September 30, 2024    65,380   $9.81    3.4 
Exercisable - September 30, 2024    60,799   $9.81    2.7 

 

The majority of the Share-based compensation expenses included in the Condensed consolidated statements of comprehensive under General and Administrative.

 

2)A summary of the Company's RSUs, granted to employees, directors, under option plans is as follows:

 

   September 30 2024 
   Number of RSUs   Weighted-Average Grant Date Fair Value 
RSUs outstanding at the beginning of the year   71,280   $10.35 
Granted during the period   
-
    
-
 
Vested during the period   (28,228)  $3.79 
Forfeited during the period   (6,798)  $6.35 
Outstanding as of September 30, 2024   36,254   $6.15 

 

The majority of the RSUs expenses included in the Condensed consolidated statements of comprehensive under General and Administrative.

 

F-21

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 8 – BASIC AND DILUTED LOSS PER SHARE:

 

Basic net loss per share is computed using the weighted average number of shares of common stock and pre-funded warrants and fully vested RSUs outstanding during the period, net of treasury shares. In computing diluted loss per share, basic loss per share is adjusted to take into account the potential dilution that could occur upon the exercise of options and RSUs granted under employee stock compensation plans, and the exercise of warrants using the treasury stock method.

 

Diluted loss per share excludes 4,602,053 shares underlying outstanding warrants, 65,380 shares underlying outstanding options, and 36,254 shares underlying outstanding RSUs for the three and nine months ended September 30, 2024, because the effect of their inclusion in the computation would be antidilutive.

 

Diluted loss per share excludes 1,047,589 shares underlying outstanding warrants, 90,377 shares underlying outstanding options, and 72,945 shares underlying outstanding RSUs for the three and nine months ended September 30, 2023, because the effect of their inclusion in the computation would be antidilutive.

 

The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:

 

   Three months ended
September 30,
   Nine months ended
September 30,
 
   2024   2023   2024   2023 
Numerator:                
                 
Net loss  $(511)  $(867)  $(2,575)  $(4,355)
                     
Denominator:                    
                     
Common shares outstanding used in computing net loss per share attributable to common shareholders   6,014,548    2,389,296    3,782,947    1,998,123 
                     
Pre-Funded warrants to purchase common shares   
-
    304,250    646,791    262,712 
                     
Repurchase of common stock   
-
    (7,920)   
-
    (6,600)
                     
Weighted average number of shares used in computing basic and diluted net loss per share attributable to common shareholders   

6,014,548

    2,685,626    4,429,738    2,254,235 
Net loss per share attributable to common shareholders – basic and diluted  $(0.09)  $(0.32)  $(0.59)  $(1.93)

 

F-22

 

 

ACTELIS NETWORKS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. DOLLARS IN THOUSANDS

 

NOTE 9 – REVENUES:

 

The Company operates as one operating segment (developing and marketing access broadband equipment for copper and fiber networks).

 

a.Geographic information:

 

Following is a summary of revenues by geographic areas. Revenues attributed to geographic areas, based on the location of the end customers:

 

   Nine months ended
September 30,
   Three months ended
September 30,
 
   2024   2023   2024   2023 
North America   5,316   $1,863    1,854   $454 
Europe, the Middle East and Africa   1,282    2,274    614    371 
Asia Pacific   100    452    73    20 
    6,698   $4,589   $2,541   $845 

 

b.Revenues from contract liability:

 

    Nine months ended,
September 30,
2024
    Year ended,
December 31,
2023
 
Opening balance     460       648  
Revenue recognized that was included in the contract liability balance at the beginning of the year     (607 )     (544 )
Additions     584       356  
Remaining performance obligations     437       460  

 

As of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligation is $437, and the Company will recognize this revenue over the next 51 months.

 

c.Customers representing 10% or more of net revenues and the amount of revenues recognized are as follows:

 

   Three months ended
September 30, 2024
   Nine months ended
September 30, 2024
 
Customer A   45%  $1,143    18%  $1,205 
Customer B   2%  $51    34%  $2,227 
Customer C   10%  $254    6%  $401 

 

   Three months ended
September 30, 2023
   Nine months ended
September 30, 2023
 
Customer A   2%  $20    20%  $920 
Customer B   24%  $201    11%  $510 
Customer C   2%  $20    10%  $469 
Customer D   10%  $80    4%  $171 

 

The majority of the Company's revenues are recognized at a point in time.

 

F-23

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Actelis Networks Inc.’s (the “Company”, “we”) financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performances, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performances or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to Part II, Item 1A of this Quarterly Report on Form 10-Q and the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2023, filed on March 26, 2024, with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov.

 

In addition, forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

 

  our history of losses and need for additional capital to fund our operations and our ability to obtain additional capital on acceptable terms, or at all;
     
  our ability to protect our intellectual property and continue to innovate;

 

  our success in retaining or recruiting, or changes required in, our officers, key employees or directors;

 

  the potential insufficiency of our disclosure controls and procedures to detect errors or acts of fraud;

 

  the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;

 

  the success of competing products or technologies that are or may become available;
     
  our ability to grow the business due to the uncertainty resulting from the COVID-19 pandemic or any future pandemic;

 

  our ability to comply with complex and increasing regulations by governmental authorities;

 

  our ability to regain and maintain compliance with continued listing requirements of the Nasdaq Capital Market;

 

  our ability to continue as a going concern;

 

  statements as to the impact of the political and security situations in Israel on our business, including due to the number of armed conflicts between Israel and Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon);

 

  our public securities’ potential liquidity and trading; and

 

  our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.

 

1

 

 

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. Forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate.

 

The forward-looking statements included in this Quarterly Report on Form 10-Q speak only as of the date of this filing. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date hereof.

 

References in this report to “we,” “Actelis,” “us,” “our,” or the “Company” refer to Actelis Networks, Inc. and its wholly owned subsidiary. References to our “management” or our “management team” refer to our officers and directors. You should read the following discussion of our historical performance, financial condition and future prospects in conjunction with the management’s discussion and analysis of financial conditions and results of operations and the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 26, 2024 (referred to herein as the “Annual Report”). The following discussion and analysis of our financial condition and results of operations should also be read in conjunction with the condensed consolidated financial statements (including the notes thereto) contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risk and uncertainties. For further information on items that could impact our future operating performance or financial condition, see the sections titled “Risk Factors” included in the Annual Report and the Special Note Regarding Forward Looking Statements above.

 

Overview

 

We are a market leader in cyber-hardened, rapid-deployment networking solutions for wide-area IoT applications including federal, state and local government, intelligent traffic systems, military, utility, rail, telecom and campus applications. Our unique portfolio of hybrid fiber, environmentally hardened aggregation switches, high density Ethernet devices, advanced management software and cyber-protection capabilities, unlocks the hidden value of essential networks, delivering safer connectivity for rapid, cost-effective deployment.

 

Our networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines which our patented technology can upgrade to Fiber-grade to jointly create what we believe to be a highly cost-effective, secure and quick-to-deploy network. Our patent protected hybrid fiber networking solutions deliver excellent communication over fiber to locations that may be easy to reach with new fiber. However, for locations that are difficult, or too costly to reach with fiber, we can upgrade existing copper lines to deliver cyber-hardened, high-speed connectivity without needing to replace the existing copper infrastructure with new fiber. We believe that such hybrid fiber-copper networking solution has distinct advantages in most real-life installations, while providing significant budget savings and accelerating deployment of modern IoT networks, as based on our experience, most IoT projects have challenging, hard to reach with fiber locations which may explode such projects’ timeline and budgets. We believe that our solutions can provide connectivity over either fiber or copper with speeds of up to multi-Gigabit communication, while supporting Fiber-grade reliability and quality.

 

A primary focus of ours is to provide our customers with a cyber-secure network solution. We currently offer Triple-Shield protection of data delivered with coding, scrambling and encryption of the network traffic. We also provide secure, encrypted access to our network management software, and are working to further enhance system-level and device-level software protection. We are also working to introduce additional capabilities for network-wide cyber protection software as an additional SW and license-based service.

 

When high speed, long reach, reliable and secure connectivity is required, network operators usually resort to using wireline communication over physical communication lines such as fiber, coax and copper, rather than wireless communication that is more limited in performance, reliability, reach and security. However, new fiber wireline infrastructure is costly to deploy, involves lengthy civil works to install, and, based on our internal calculations, often accounts for more than 50% of total cost of ownership (ToC) and time to deploy wide-area IoT projects.

 

2

 

 

Providing new fiber connectivity to hard-to-reach locations is especially costly and time-consuming, often requiring permits for boring, trenching, and right-of-way, sometimes done over many miles. Connecting such hard-to-reach locations may cause significant delays and budget overruns in IoT projects. Our solutions aim to solve these challenges by instantly enhancing performance of such existing copper and coax infrastructure to fiber-grade performance, through the use of advanced signal processing an unique, patented network architecture, without the need to run new fiber to hard-to-reach locations; thus, effectively accelerating deployment of many IoT projects, as we estimate, sometimes from many months to only days. The result for the network owner isa hybrid network that optimizes the use of both new Fiber (where available) as well as upgraded, fiber-grade copper and coax that is now modernized, digitized and cyber-hardened. This unique hybrid network approach is making IoT projects often significantly more affordable, fast to deploy and predictable to plan and budget.

 

In addition, our solutions can also provide power over existing copper and coax lines to remotely power up network elements and IoT components connected to them (like cameras, small cell and Wi-Fi base stations sensors etc.). Connecting power lines to millions of IoT locations can be costly and very time consuming as well (similar to data connectivity, for the same reason-need for civil works). By offering the ability to combine power delivery over the same existing copper and coax lines that we use for high-speed data, we believe our solutions are solving yet another important challenge in connecting hard-to-reach locations. We believe that combining communication and power over the same existing lines is particularly important to help connect many fifth generation, or 5G, small cells and Wi-Fi base stations, as high cost of connectivity and power is often slowing their deployment.

 

Since our inception, our business was focused on serving telecommunication service providers, also known as Telcos, to provide connectivity for enterprises and residential customers. Our products and solutions have been deployed with more than 100 telecommunication service providers worldwide, in enterprise, residential and mobile base station connectivity applications. In recent years, as we have further developed our technology and introduced additional products, we turned our focus on serving the wide-area IoT markets. Our operations are focused on our fast-growing IoT business, while maintaining our commitment to our existing Telco customers. In 2023, we introduced new product offering, some of which could serve both the IoT markets and our Telco customers.

 

Recent Developments

 

Nasdaq Listing Compliance

 

On August 25, 2023, we received a notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to our failure to maintain a minimum of $2,500,000 in shareholders’ equity (the “Minimum Shareholders’ Equity Requirement”) or any alternatives to such requirement. In order to maintain our listing on the Nasdaq Capital Market, we submitted a plan of compliance addressing how we intended to regain compliance. On March 27, 2024, we received a delist determination letter from Nasdaq advising us that the Staff had determined to delist our securities from Nasdaq due to non-compliance with the Minimum Shareholders’ Equity Requirement, unless we timely request a hearing before the Nasdaq Hearings Panel (the “Panel”). We timely requested a hearing before the Panel.

 

On August 27, 2024, we received formal written notice from Nasdaq confirming that we have evidenced compliance with all applicable criteria for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders’ Equity Requirement. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), we will remain subject to a panel monitor for equity compliance through August 27, 2025.

 

Hamas-Israel War

 

In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and these terrorist organizations in parallel continued rocket and terror attacks. Nevertheless, our clinical and business development activities remain on track. See also Risk Factors – “We conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations and Israel’s war against them, may affect our operations”.

 

QIND Term Sheet

 

On May 23, 2024, we announced that we have entered into a binding term sheet (as amended, the “Term Sheet”) with Quality Industrial Corp, a Nevada corporation traded on the OTC under the symbol QIND (“Target”), and Ilustrato Pictures International Inc., a Nevada corporation, providing for the potential acquisition of between 61% to 75% of the issued and outstanding shares of the Target’s share capital.

 

On November 11, 2024, the Company notified the Target that the Term Sheet is terminated.

 

3

 

 

Results of Operations

 

The table below provides our results of operations for the periods indicated.

 

   Three months ended
September 30
   Nine months ended
September 30
 
   2024   2023   2024   2023 
   (dollars in thousands)   (dollars in thousands) 
Revenues   2,541    845    6,698    4,589 
Cost of revenues   798    619    2,792    3,043 
Gross profit   1,743    226    3,906    1,546 
Research and development expenses, net   543    691    1,793    2,117 
Sales and marketing, net   727    691    2,001    2,332 
General and administrative, net   790    971    2,398    2,805 
Other income, net   -    -    (163)   - 
Operating loss   (317)   (2,127)   (2,123)   (5,708)
Interest expenses   (246)   (161)   (590)   (512)
Other Financial income (expenses), net   52    1,421    138    1,865
Net Comprehensive Loss for the period   (511)   (867)   (2,575)   (4,355)

 

Three and Nine Months Ended September 30, 2024, Compared to Three and Nine Months Ended September 30, 2023

 

Revenues

 

Our revenues for the three months ended September 30, 2024 amounted to $2.54 million compared to $0.85 million for the three months ended September 30, 2023. The increase from the corresponding period was primarily attributable to an increase of $1.4 million of revenues generated from North America driven by volume increase and a renewal of a service and software contract and an increase of $0.3 million of revenues generated from Asia Pacific and Europe, the Middle East and Africa driven by volume increase.

 

Our revenues for the nine months ended September 30, 2024 amounted to $6.7 compared to $4.6 million for the nine months ended September 30, 2023. The increase from the corresponding period was primarily attributable to an increase of $3.4 million in revenues generated from North America associated with volume increase and a renewal of a service and software contract offset by decrease of $1.3 million in revenues generated from Asia Pacific and Europe, the Middle East and Africa associated with completed projects in the prior year period.

 

Cost of Revenues

 

Our cost of revenues for the three months ended September 30, 2024, amounted to $0.8 million compared to $0.6 million for the three months ended September 30, 2023. The increase from the corresponding period was primarily attributable to the increase in revenues as well as change in the product mix as well as indirect costs not increasing significantly with revenues growing.

 

Our cost of revenues for the nine months ended September 30, 2024, amounted to $2.8 million compared to $3.0 million for the nine months ended September 30, 2023. The decrease from the corresponding period was primarily attributable to the change in regional mix of revenue of an increase in North America revenues, which are more profitable, and a decrease in Europe, Middle East and Africa revenues which are less profitable as well as indirect costs not increasing significantly with revenues growing.

 

Research and Development Expenses

 

Our research and development expenses for the three months ended September 30, 2024, amounted to $0.5 million compared to $0.7 million for the three months ended September 30, 2023. The decrease is primarily attributable to cost reduction measures taken.

 

Our research and development expenses for the nine months ended September 30, 2024, amounted to $1.7 million compared to $2.1 million for the nine months ended September 30, 2023. The decrease is primarily attributable to cost reduction measures taken.

 

4

 

 

Sales and Marketing Expenses

 

Our sales and marketing expenses for the three months ended September 30, 2024, amounted to $0.7 million compared to $0.7 for the three months ended September 30, 2023.

 

Our sales and marketing expenses for the nine months ended September 30, 2024 amounted to $2.0 million compared to $2.3 for the nine months ended September 30, 2023. The decrease was mainly due to cost reduction measures taken.

 

General and Administrative Expenses

 

Our general and administrative expenses for the three months ended September 30, 2024, amounted to $0.8 million compared to $1.0 million for the three months ended September 30, 2023. The decrease is driven by cost reduction measures taken.

 

Our general and administrative expenses for the nine months ended September 30, 2024, amounted to $2.4 million compared to $2.8 million for the nine months ended September 30, 2023. The decrease is driven by cost reduction measures taken.

 

Other Income

 

Our Other Income for the nine months ended September 30, 2024 amounted to $163,000 compared to none for the nine months ended September 30, 2023. The increase is driven by a government grant from the State of Israel associated with the Iron Swords war received during the second quarter of 2024.

 

Operating Loss

 

Our operating loss for the three months ended September 30, 2024, was $0.3 million, compared to an operating loss of $2.1 million for the three months ended September 30, 2023. The decrease was mainly due to the increase in revenues, improved gross margin due to regional revenue mix, and cost reduction measures taken, reducing operating expenses.

 

Our operating loss for the nine months ended September 30, 2024, was $2.1 million, compared to an operating loss of $5.7 million for the nine months ended September 30, 2023. The decrease was mainly due to the increase in revenues, improved gross margin due to regional revenue mix, and cost reduction measures taken, reducing operating expenses.

 

Financial Expenses, Net and Interest Expenses

 

Our financial income, net was $52,000 million and our interest expense was $0.2 million for the three months ended September 30, 2024 compared to financial income, net of $1.4 million and including $0.2 million interest expenses for the three months ended September 30, 2023. The increase is mainly due to financial income in the prior year from bank deposits and exchange rate differences not repeated in current period.

 

Our financial income, net was $138,000 and our interest expense was $0.6 million for the nine months ended September 30, 2024 compared to financial income, net of $1.9 million and interest expense of $0.5 million interest expenses for the nine months ended September 30, 2023. The increase is mainly due to financial income in the prior year from bank deposits and exchange rate differences not repeated in current period.

 

Net Loss

 

Our net loss for the three months ended September 30, 2024, was $0.5 million, compared to net loss of $0.9 million for the three months ended September 30, 2023. This decrease was primarily due to the increase in revenues, improved gross margin due to regional revenue mix, and cost reduction measures taken, reducing operating expenses, partially offset by financial income in the prior year not repeating itself.

 

Our net loss for the nine months ended September 30, 2024, was $2.6 million, compared to net loss of $4.4 million for the nine months ended September 30, 2023. This decrease was primarily due to the increase in revenues, improved gross margin due to regional revenue mix, and cost reduction measures taken, reducing operating expenses, partially offset by financial income in the prior year not repeating itself.

 

5

 

 

Non-GAAP Financial Measures

 

(U.S. dollars in thousands)  Three months Ended
September 30,
2024
   Three months Ended
September 30,
2023
   Nine months Ended
September 30,
2024
   Nine months Ended
September 30,
2023
 
Revenues  $2,541   $845   $6,698   $4,589 
GAAP net loss   (511)   (867)   (2,575)   (4,355)
Interest Expense   246    161    590    512 
Other Financial expenses (income), net   (52)   (1,421)   (138)   (1,865)
Tax Expense   1    18    33    58 
Fixed asset depreciation expense   3    7    10    20 
Stock based compensation   80    106    259    298 
Research and development, capitalization   -    113    -    371 
Other one-time costs and expenses (income)   -    120    (189)   343 
Non-GAAP Adjusted EBITDA   (233)   (1,763)   (2,010)   (4,618)
GAAP net loss margin   (20.11)%   (102.60)%   (38.44)%   (94.90)%
Adjusted EBITDA margin   (9.17)%   (208.64)%   (30.00)%   (100.63)%

 

Use of Non-GAAP Financial Information

 

Non-GAAP Adjusted EBITDA and Adjusted EBITDA margin are Non-GAAP financial measures. In addition to reporting financial results in accordance with GAAP, we provide Non-GAAP supplemental operating results adjusted for certain items, including: financial expenses, which are interest, financial instrument fair value adjustments, exchange rate differences of assets and liabilities, stock based compensation expenses, depreciation and amortization expense, tax expense, and impact of development expenses ahead of product launch. We adjust for the items listed above and show non-GAAP financial measures in all periods presented, unless the impact is clearly immaterial to our financial statements. When we calculate the tax effect of the adjustments, we include all current and deferred income tax expense commensurate with the adjusted measure of pre-tax profitability.

  

We utilize the adjusted results to review our ongoing operations without the effect of these adjustments but not for comparison to budgeted operating results.. We believe the supplemental adjusted results are useful to investors because they help them compare our results to previous periods and provide important insights into underlying trends in the business and how management oversees and optimizes our business operations on a day-to-day basis. We exclude the costs in calculating adjusted results to allow us and investors to evaluate the performance of the business based upon its expected ongoing operating structure. We believe the adjusted measures, accompanied by the disclosure of the costs of these programs, provides valuable insight to our financial performance. Adjusted results should be considered only in conjunction with results reported according to GAAP.

 

   For the three months ended
September 30
   For the nine months ended
September 30
 
(U.S. dollars in thousands)  2024   2023   2024   2023 
Revenues  $2,541   $845   $6,698   $4,589 
                     
Non-GAAP Adjusted EBITDA   (233)   (1,763)   (2,010)   (4,618)
                     
As a percentage of revenues   (9.17)%   (208.64)%   (30.00)%   (100.63)%

 

Liquidity and Capital Resources

 

Since our inception, we have financed our operations primarily through the sale of equity securities, debt financing, convertible loans and royalty-bearing grants that we received from the Israel Innovation Authority. Our primary requirements for liquidity and capital are to finance working capital, capital expenditures and general corporate purposes.

 

Our future capital requirements will be affected by many factors, including our revenue growth, the timing and extent of investments to support such growth, the expansion of sales and marketing activities, increases in general and administrative costs, repayment of principal of our existing credit line, working capital to support securing raw material supply and many other factors as described under “Risk Factors.”

 

6

 

 

To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all. In particular, the repercussions from the COVID 19 pandemic, as well as the war in Israel and the war between Russia and the Ukraine, has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital.

 

On June 5, 2024, we entered into an inducement agreement with a certain holder of certain of our existing warrants to purchase up to an aggregate of 999,670 shares of our common stock originally issued on May 8, 2023, with a five and one-half year term, at an exercise price of $2.75 per share (the “May 2023 Warrants”). Pursuant to the inducement agreement, the holder agreed to exercise for cash its May 2023 Warrants to purchase an aggregate of 999,670 shares of our common stock at an exercise price of $2.75 per share, in consideration of our agreement to issue new common stock purchase warrants (the “June 2024 Warrants”), as described below, to purchase up to an aggregate of 1,999,340 shares of our common stock, at an exercise price of $2.00 per share. The closing of the June 2024 Warrant Inducement occurred on June 6, 2024, and resulted in gross proceeds from the exercise of the existing warrants by the holder to the Company of $3.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

 

On June 30, 2024, we entered into an inducement letter with a holder of our June 2024 Warrants, to purchase up to an aggregate of 999,670 shares of the June 2024 Warrants, originally issued on June 6, 2024, with a twenty-four month term, at an exercise price of $2.00 per share. Pursuant to the inducement letter, the holder agreed to exercise for cash its warrants to purchase an aggregate of 999,670 shares of our common stock at an exercise price of $2.00 per share, in consideration of our agreement to issue new common stock purchase warrants (the “July 2024 Warrants”), as descried below, to purchase up to an aggregate of 1,999,340 shares of our common stock, at an exercise price of $1.75 per share. The closing of the July 2024 Warrant Inducement occurred on July 2, 2024, and resulted in gross proceeds from the exercise of the existing warrants by the holder to the Company of $2.25 million, before deducting placement agent fees and other offering expenses payable by the Company.

 

On September 18, 2024, we filed a shelf registration statement on Form S-3 (the “Registration Statement”). Pursuant to the Registration Statement, we may offer and sell securities having an aggregate public offering price of up to $50.0 million. In connection with the filing of the Registration Statement, on September 25, 2024, we entered into a sales agreement with H.C. Wainwright & Co. (the “Sales Agent”), pursuant to which we may issue and sell shares of our common stock for an aggregate offering price of up to $3.4 million under an at-the-market offering program (the “ATM”), which is included in the $50.0 million of securities that may be offered pursuant to the Registration Statement. Pursuant to the ATM, we will pay the Sales Agent a commission rate of up to 3.0% of the gross proceeds from the sale of any shares of our common stock. We are not obligated to make any sales of shares under the ATM. As of September 30, 2024, we have sold 227,939 shares of our common stock and received approximately $317,000 in net proceeds under the ATM.

 

As discussed in Note 1(c) to the condensed consolidated financial statements appearing elsewhere in this Quarterly report on Form 10-Q, we have incurred significant losses and negative cash flows from operations and incurred losses of $2.5 million and $6.2 million for the nine months ended September 30, 2024 and the year ended December 31, 2023, respectively. During the nine months ended September 30, 2024 and the year ended December 31, 2023, we had negative cash flows from operations of $4.7 million and $6.5 million, respectively. As of September 30, 2024, we had negative working capital and an accumulated deficit of $42.2 million.

 

As of September 30, 2024, we had cash on hand (including short term deposits and restricted bank deposits) of approximately $2.3 million and long-term deposits, restricted bank deposits and restricted cash of $300,000. We monitor our cash flow projections on a current basis and take active measures to obtain the funding we require to continue our operations, as well as make adjustments to our cost structure that were done year to date. However, these cash flow projections are subject to various uncertainties concerning their fulfilment, such as the ability to increase revenues by attracting and expanding our customer base or reducing cost structure. If we are not successful in generating sufficient cash flow or completing additional financing, then we will need to execute additional cost reduction actions that have been planned. Our transition to profitable operations is dependent on generating a level of revenue adequate to support our cost structure. We expect to fund operations using cash on hand, through operational cash flows and raising additional proceeds. There are no assurances, however, that we will be able to generate the revenue necessary to support our cost structure or that we will be successful in obtaining the level of financing necessary for our operations. Management has evaluated the significance of these conditions and has determined that we do not have sufficient resources to meet our operating obligations for at least one year from the issuance date of these condensed consolidated financial statements. These factors raise substantial doubt about the Company's ability to continue as a going concern. These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments that might result from the outcome of this uncertainty.

 

7

 

 

Cash Flows

 

The table below, for the periods indicated, provides selected cash flow information:

 

(U.S. dollars in thousands)  Nine Months
Ended
September 30,
2024
   Nine Months
Ended
September 30,
2023
 
Net cash used in operating activities  $(4,781)  $(5,194)
Net cash provided by (used in) investing activities   197    1,430 
Net cash provided by financing activities   1,624    2,586 
Net change in cash  $(2,974)  $(1,190)

 

As of September 30, 2024, we had cash, cash equivalents, and restricted cash of $2.5 million compared to $3.1 million of cash, cash equivalents and restricted cash as of September 30, 2023.

 

Cash used in operating activities amounted to $4.7 million for the nine months ended September 30, 2024, compared to $5.2 for the nine months ended September 30, 2023. The decrease in cash used in operating activities was mainly due to cost reduction measures taken.

 

Net cash provided by investing activities was $0.2 million for the nine months ended September 30, 2024, compared to cash used in investing activities of $1.4 for the nine months ended September 30, 2023. The decrease from the corresponding period was mainly due to the reduction in short-term bank deposits.

 

Net cash provided by financing activities was $1.6 million for the nine months ended September 30, 2024, compared to $2.6 million for the nine months ended September 30, 2023. The decrease is related to the repayment of long-term loan, offset by funds raised from an investor warrant exercise. See notes 2 to the condensed consolidated financial statements

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities.

 

Critical Accounting Policies and Estimates

 

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the applicable periods. We evaluate our estimates, assumptions and judgments on an ongoing basis. Our estimates, assumptions and judgments are based on historical experience and various other factors that we believe to be reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our condensed consolidated financial statements, which, in turn, could change the results from those reported.

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles issued by the Financial Accounting Standards Board, or FASB. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

 

Our significant accounting policies include revenue from contracts with customers which is more fully described in the notes to our condensed consolidated financial statements appearing elsewhere in this Quarterly report on Form 10-Q and our annual financial statements for the year ended December 31, 2023, including the footnotes, for a description of our significant accounting policies. We believe that these accounting policies discussed are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

 

8

 

  

Item 3. Quantitative and Qualitative Disclosure About Market Risk.

 

Not required for a smaller reporting company.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

We continued to conduct ongoing evaluation of the effectiveness of our “disclosure controls and procedures”, as defined by Rules 13a-15(e) and 15d-15(e) of Exchange Act, as of September 30, 2024, the end of the period covered by this Quarterly Report. This evaluation, which was performed under the supervision and with the participation of management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), is performed to determine whether our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Disclosure controls and procedures, no matter how well designed and effectively operated, can only provide reasonable assurance of achieving their control objectives.

 

Based upon that evaluation, our CEO and CFO concluded our disclosure controls and procedures were not effective as of the period covered by this Quarterly Report on Form 10-Q due to the material weakness discussed below.

 

Management’s report on internal control over financial reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the consolidated financial statements for external reporting purposes in accordance with GAAP.

 

Because of its inherent limitations, our internal control over financial reporting may not prevent or detect all misstatements, including the possibility of human error, the circumvention or overriding of controls or fraud. Effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. Also, projections of any evaluation of effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate over time.

 

Under the supervision and with the participation of the CEO and the CFO, management conducted an evaluation of the effectiveness of our internal control over financial reporting as of September 30, 2024. We performed an assessment of the effectiveness of our internal control over financial reporting based on the framework described in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this evaluation, our management concluded that we did not maintain effective internal control over financial reporting as of September 30, 2024 given the existence of the previously identified material weakness described below having not been remediated as of the last day of the period covered by this Quarterly Report. 

 

Material Weakness

 

We have identified one material weakness in our design and operation of our internal control over financial reporting in connection with the preparation of our financial remediated as of September 30, 2024.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. The Company’s management, including our CEO and CFO, concluded that, as of September 30, 2024:

 

9

 

 

We lacked a sufficient complement of professionals with an appropriate level of accounting knowledge, training and experience to maintain appropriate segregation of duties in our finance and accounting functions.

 

Our independent registered public accounting firm will not be required to opine on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer an “emerging growth company” as defined in the JOBS Act.

 

Remediation Plan and Status

 

We have taken and intend to continue to take actions to remediate the material weakness described above. To remediate this material weakness, we continue to map, document and test our internal controls (recently, with the assistance of a third-party accounting firm with specific expertise in SOX compliance), and accordingly, we continued to make progress in our internal controls plan. Among other procedures, management has executed the following remedial actions:

 

  Hired new financial experts and increasing the number of financial personnel.

 

  Continued to map, document and test our internal controls, with the assistance of a third-party accounting firm with specific expertise in SOX compliance.

 

  Implemented new control procedures over certain areas identified as requiring enhancement in order to address the lack of a sufficient number of finance personnel to allow for adequate segregation of duties.

 

In addition to the actions underway, we continue to add enhancements to our internal controls over financial reporting in 2024. Additional remedial actions include:

 

  Maintain or increase the level and design of segregation of duties, including maintaining or growing the quality and number of finance personnel

 

  Continue to document and test annually our internal control over financial reporting

 

  Continue engagement with an outside accounting firm with specific SOX and Internal Control expertise

 

  Continued hiring of additional accounting, information technology, and internal controls resources who possess public company accounting, auditing and reporting expertise

 

The actions we are taking are subject to ongoing senior management review, as well as oversight of the audit committee of our Board. We also may conclude that additional measures may be required to remediate the material weaknesses or determine to modify the remediation plans described above. We will not be able to fully remediate this material weakness until these steps have been completed and have been operating effectively. We will continue to monitor the design and effectiveness of these and other processes, procedures, and controls and make any further changes management deems appropriate.

 

In addition to the items noted above, as we continue to evaluate, remediate and improve our internal control over financial reporting, executive management may elect to implement additional measures to address control deficiencies or may determine that the remediation efforts described above require modification. Executive management, in consultation with and at the direction of our Audit Committee and an expert outside consultant, will continue to assess the control environment and the above-mentioned efforts to remediate the underlying causes of the identified material weakness.

 

Although we plan to complete this remediation process as quickly as possible, we are unable, at this time to estimate how long it will take; and our efforts may not be successful in remediating the deficiencies or material weaknesses.

 

Notwithstanding the material weakness set forth above, based on the performance of additional procedures by management designed to ensure reliability of financial reporting, the Company’s management has concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q, fairly present, in all material respects, the Company’s financial position, results of operations and cash flows as of the dates, and for the periods presented, in conformity with GAAP.

 

Changes in Internal Controls over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

10

 

 

Part II - Other Information

 

Item 1. Legal Proceedings.

 

From time to time, we are involved in various claims and legal actions arising in the ordinary course of business. To the knowledge of our management, there are no legal proceedings currently pending against us which we believe would have a material effect on our business, financial position or results of operations and, to the best of our knowledge, there are no such legal proceedings contemplated or threatened.

 

Item 1A. Risk Factors.

 

Except as set forth below in this Item 1A and the Risk Factors included in our previous filings made with the SEC, there have been no material changes to our risk factors from those disclosed in “Part I. Item 1A. Risk Factors” in the Form 10-K filed with the SEC on March 26, 2024.

 

Conditions in the Middle East and in Israel, where our research and development facilities are located, may harm our operations.

 

Our office where we conduct our research and development, operations, sales outside the Americas, and administration activities, is located in Israel. Many of our employees are residents of Israel. Most of our officers and directors are residents of Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, and between Israel and the Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon).

 

In particular, in October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally kidnapped many Israeli civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign against Hamas and Hezbollah and these terrorist organizations in parallel continued rocket and terror attacks. As a result of the events of October 7, 2023 whereby Hamas terrorists invaded southern Israel and launched thousands of rockets in a widespread terrorist attack on Israel, the Israeli government declared that the country was at war and the Israeli military began to call-up reservists for active duty. As of the date of this Quarterly Report on Form 10-Q, we have not been impacted by any absences of personnel at our service providers or counterparties located in Israel. Military service call ups that result in absences of personnel from us for an extended period of time may materially and adversely affect our business, prospects, financial condition and results of operations. As of the date of this Quarterly Report, we currently have 42 full-time employees, with 33 employees located in Israel and 9 employees located outside of Israel.

 

Since the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced any material disruptions to our operations. We have the ability, if necessary, to shift our manufacturing from Israel to other countries where we have business partners, and we have not had customers in Israel in the last year. However, the intensity and duration of the war in the Middle East is difficult to predict at this stage, as are such war’s economic implications on the Company’s business and operations and on Israel’s economy in general. if the war in the other fronts, such as Lebanon, Syria and the West Bank expands further, our operations may be adversely affected.

 

In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the hostilities. Such clashes may escalate in the future into a greater regional conflict. In addition, Iran recently launched a direct attack on Israel involved hundreds of drones and missiles, and has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business.

 

Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. In recent years, the hostilities involved missile strikes against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel.

 

Our commercial insurance does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations. To-date, we have received Israeli government war related support funding of approximately $100,000.

 

11

 

 

Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. To date, these initiatives have been substantially put on hold. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.

 

If we fail to comply with the continued listing requirements of the Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

Nasdaq has established certain standards for the continued listing of a security on the Nasdaq Capital Market. The standards for continued listing include, among other things, that the minimum bid price for the listed securities not fall below $1.00 per share for a period of 30 consecutive trading days and that we maintain a minimum of $2,500,000 in shareholders’ equity.

 

We have in the past, and may in the future, be unable to comply with certain of the listing standards that we are required to meet to maintain the listing of our ordinary shares on Nasdaq.

 

For instance, on August 25, 2023, we received a notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) due to our failure to maintain a minimum of $2,500,000 in shareholders’ equity (the “Minimum Shareholders’ Equity Requirement”) or any alternatives to such requirement. In order to maintain our listing on the Nasdaq Capital Market, we submitted a plan of compliance addressing how we intended to regain compliance

 

On August 27, 2024, we received formal written notice from Nasdaq confirming that we have evidenced compliance with all applicable criteria for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550, including the Minimum Shareholders’ Equity Requirement. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), we will remain subject to a panel monitor for equity compliance through August 27, 2025.

 

In addition, on May 20, 2024, the Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company’s common stock to maintain a minimum bid price of $1.00 per share. On June 20, 2024, the Company received a letter from Nasdaq that, for the 10 consecutive business days from June 5, 2024 to June 28, 2024, the closing bid price of the Company’s common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

 

If we fail to satisfy the continued listing requirements of Nasdaq, such as minimum stockholders’ equity requirements or minimum bid price requirements, Nasdaq may take steps to delist our shares of common stock. Such a delisting would have a negative effect on the price of our shares of common stock, impair the ability to sell or purchase our shares of common stock when persons wish to do so, and any delisting materially adversely affect our ability to raise capital or pursue strategic restructuring, refinancing or other transactions on acceptable terms, or at all. Delisting from Nasdaq could also have other negative results, including the potential loss of institutional investor interest and fewer business development opportunities, as well as a limited amount of news and analyst coverage of us. Delisting could also result in a determination that our shares of common stock are a “penny stock,” which would require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary market for our shares of common stock. In the event of a delisting, we would attempt to take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our shares of common stock to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our shares of common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

12

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

13

 

 

Item 6. Exhibits.

 

Exhibit
Number
  Description of Exhibits
31.1*   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Schema
101.CAL*   Inline XBRL Taxonomy Calculation Linkbase
101.DEF*   Inline XBRL Taxonomy Definition Linkbase
101.LAB*   Inline XBRL Taxonomy Label Linkbase
101.PRE*   Inline XBRL Taxonomy Presentation Linkbase
104*   Cover Page Interactive Data File (formatted as Inline XBRL document and contained in Exhibit 101)

 

*Filed herewith

 

14

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Actelis Networks, Inc.
     
Date: November 14, 2024 By: /s/ Tuvia Barlev
    Tuvia Barlev
    Chief Executive Officer
(Principal Executive Officer)
     
Date: November 14, 2024 By: /s/ Yoav Efron
    Yoav Efron
   

Chief Financial Officer and

Deputy Chief Executive Officer
(Principal Financial and Accounting Officer)

 

15

 

0.00 false --12-31 Q3 0001141284 0001141284 2024-01-01 2024-09-30 0001141284 2024-11-14 0001141284 2024-09-30 0001141284 2023-12-31 0001141284 us-gaap:RedeemableConvertiblePreferredStockMember 2024-09-30 0001141284 us-gaap:RedeemableConvertiblePreferredStockMember 2023-12-31 0001141284 asns:NonVotingCommonStockMember 2024-09-30 0001141284 asns:NonVotingCommonStockMember 2023-12-31 0001141284 2023-01-01 2023-09-30 0001141284 2024-07-01 2024-09-30 0001141284 2023-07-01 2023-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2022-12-31 0001141284 asns:WarrantsToPlacementAgentMember 2022-12-31 0001141284 us-gaap:CommonStockMember 2022-12-31 0001141284 asns:NonVotingCommonStockMember 2022-12-31 0001141284 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001141284 2022-12-31 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2023-01-01 2023-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2023-01-01 2023-09-30 0001141284 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001141284 asns:NonVotingCommonStockMember 2023-01-01 2023-09-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2023-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2023-09-30 0001141284 us-gaap:CommonStockMember 2023-09-30 0001141284 asns:NonVotingCommonStockMember 2023-09-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001141284 2023-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2023-12-31 0001141284 asns:WarrantsToPlacementAgentMember 2023-12-31 0001141284 us-gaap:CommonStockMember 2023-12-31 0001141284 asns:NonVotingCommonStockMember 2023-12-31 0001141284 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001141284 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001141284 asns:NonVotingCommonStockMember 2024-01-01 2024-09-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2024-01-01 2024-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2024-01-01 2024-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2024-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2024-09-30 0001141284 us-gaap:CommonStockMember 2024-09-30 0001141284 asns:NonVotingCommonStockMember 2024-09-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2023-06-30 0001141284 asns:WarrantsToPlacementAgentMember 2023-06-30 0001141284 us-gaap:CommonStockMember 2023-06-30 0001141284 asns:NonVotingCommonStockMember 2023-06-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001141284 2023-06-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2023-07-01 2023-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2023-07-01 2023-09-30 0001141284 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001141284 asns:NonVotingCommonStockMember 2023-07-01 2023-09-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001141284 asns:RedeemableConvertiblePreferredStockAmountMember 2024-06-30 0001141284 asns:WarrantsToPlacementAgentMember 2024-06-30 0001141284 us-gaap:CommonStockMember 2024-06-30 0001141284 asns:NonVotingCommonStockMember 2024-06-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001141284 2024-06-30 0001141284 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001141284 asns:WarrantsToPlacementAgentMember 2024-07-01 2024-09-30 0001141284 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001141284 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001141284 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-09-30 0001141284 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-12-31 0001141284 asns:CustomerAMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerAMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001141284 asns:CustomerBMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerBMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001141284 asns:CustomerCMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerCMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001141284 asns:CustomerDMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerDMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001141284 asns:CustomerEMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerEMember asns:TradeRecievableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001141284 us-gaap:CatastropheMember asns:EconomicInjuryDisasterLoanMember 2020-07-01 0001141284 asns:EconomicInjuryDisasterLoanMember 2020-07-01 0001141284 asns:EconomicInjuryDisasterLoanMember 2024-09-30 0001141284 2020-12-09 0001141284 2020-12-31 0001141284 2021-01-31 0001141284 2021-11-01 2021-11-30 0001141284 2021-11-30 0001141284 2022-12-21 0001141284 2024-02-01 2024-02-29 0001141284 2024-04-01 2024-04-30 0001141284 2024-05-01 2024-05-31 0001141284 asns:MigdalorLoanMember 2024-05-01 2024-05-31 0001141284 2024-02-29 0001141284 2024-02-29 2024-02-29 0001141284 2024-07-31 0001141284 2024-07-01 2024-07-31 0001141284 srt:SubsidiariesMember 2024-01-15 0001141284 asns:FederalSOFRRateMember 2024-01-15 2024-01-15 0001141284 2024-01-15 2024-01-15 0001141284 asns:NewCreditFacilityMember 2024-01-01 2024-09-30 0001141284 srt:SubsidiariesMember 2024-09-30 0001141284 us-gaap:SeriesBPreferredStockMember 2016-08-24 0001141284 2023-01-01 2023-12-31 0001141284 us-gaap:CommonStockMember 2023-01-01 2023-01-31 0001141284 us-gaap:CommonStockMember 2023-02-01 2023-02-28 0001141284 us-gaap:CommonStockMember 2023-01-01 2023-02-28 0001141284 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-30 0001141284 us-gaap:InvestorMember 2023-05-08 2023-05-08 0001141284 2023-05-08 2023-05-08 0001141284 2023-05-08 0001141284 2023-07-01 2023-07-31 0001141284 2023-08-01 2023-08-31 0001141284 asns:CommonWarrantsMember 2023-05-08 0001141284 asns:CommonWarrantsMember 2023-05-08 2023-05-08 0001141284 asns:CommonWarrantsMember 2023-09-30 0001141284 asns:AdditionalCommonWarrantsMember 2023-09-30 0001141284 asns:CommonWarrantsMember 2024-01-01 2024-09-30 0001141284 2023-05-31 2023-05-31 0001141284 us-gaap:WarrantMember 2023-05-31 0001141284 asns:UnderwriterWarrantsMember 2023-05-31 2023-05-31 0001141284 2023-12-20 2023-12-20 0001141284 us-gaap:CommonStockMember 2023-12-20 0001141284 us-gaap:CommonStockMember 2023-12-20 2023-12-20 0001141284 2024-01-01 2024-06-30 0001141284 asns:CommonWarrantsMember 2024-09-30 0001141284 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001141284 2023-12-31 2023-12-31 0001141284 us-gaap:WarrantMember 2023-12-31 0001141284 asns:HCWainwrightCoLLCMember 2023-12-31 2023-12-31 0001141284 us-gaap:WarrantMember 2023-12-31 2023-12-31 0001141284 us-gaap:CommonStockMember 2024-06-05 0001141284 us-gaap:EmployeeStockOptionMember 2023-05-08 2023-05-08 0001141284 asns:WarrantInducementAgreementJune2024Member 2024-01-01 2024-09-30 0001141284 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2024-09-30 0001141284 us-gaap:EmployeeStockOptionMember us-gaap:WarrantMember 2024-01-01 2024-09-30 0001141284 asns:JuneWarrantsMember 2024-09-30 0001141284 asns:JuneWarrantsMember 2024-01-01 2024-09-30 0001141284 us-gaap:WarrantMember 2024-09-30 0001141284 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001141284 us-gaap:WarrantMember asns:HCWainwrightCoLLCMember 2024-01-01 2024-09-30 0001141284 asns:HCWainwrightCoLLCMember 2024-01-01 2024-09-30 0001141284 asns:UnderwriterWarrantsMember 2024-01-01 2024-09-30 0001141284 asns:OfferingCostsRelatedToWarrantInducementAgreementMember 2024-09-30 0001141284 2024-06-30 2024-06-30 0001141284 asns:JuneWarrantsMember 2024-06-30 2024-06-30 0001141284 asns:WarrantInducementAgreementMember 2024-01-01 2024-09-30 0001141284 asns:JulyWarrantsMember 2024-01-01 2024-09-30 0001141284 asns:JulyWarrantsMember asns:WarrantInducementAgreementMember 2024-01-01 2024-09-30 0001141284 asns:OfferingCostsRelatedToWarrantInducementAgreementMember 2024-01-01 2024-09-30 0001141284 asns:WarrantInducementAgreementMember 2024-09-30 0001141284 us-gaap:WarrantMember asns:WarrantInducementAgreementMember 2024-09-30 0001141284 asns:HCWainwrightCoLLCMember asns:AtTheMarketOfferingAgreementMember 2024-01-01 2024-09-30 0001141284 asns:AtTheMarketOfferingAgreementMember 2024-01-01 2024-09-30 0001141284 asns:AtTheMarketOfferingAgreementMember 2024-09-30 0001141284 asns:FivePointFiveJuneWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001141284 asns:TwoYearsJuneWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001141284 asns:FivePointFiveJuneWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0001141284 asns:TwoYearsJuneWarrantsMember us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0001141284 asns:FivePointFiveJuneWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001141284 asns:TwoYearsJuneWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001141284 asns:FivePointFiveJuneWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001141284 asns:TwoYearsJuneWarrantsMember us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001141284 us-gaap:MeasurementInputExpectedTermMember 2024-09-30 0001141284 us-gaap:MeasurementInputOptionVolatilityMember 2024-09-30 0001141284 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-09-30 0001141284 us-gaap:MeasurementInputSharePriceMember 2024-09-30 0001141284 asns:WarrantsMay2023Member 2024-09-30 0001141284 srt:MinimumMember asns:WarrantsMay2023Member 2024-09-30 0001141284 srt:MaximumMember asns:WarrantsMay2023Member 2024-09-30 0001141284 asns:WarrantsDecember2023Member 2024-09-30 0001141284 srt:MinimumMember asns:WarrantsDecember2023Member 2024-09-30 0001141284 srt:MaximumMember asns:WarrantsDecember2023Member 2024-09-30 0001141284 asns:WarrantJune2024Member 2024-09-30 0001141284 srt:MinimumMember asns:WarrantJune2024Member 2024-09-30 0001141284 srt:MaximumMember asns:WarrantJune2024Member 2024-09-30 0001141284 asns:WarrantsJuly2024Member 2024-09-30 0001141284 srt:MinimumMember asns:WarrantsJuly2024Member 2024-09-30 0001141284 srt:MaximumMember asns:WarrantsJuly2024Member 2024-09-30 0001141284 asns:OtherWarrantMember 2024-09-30 0001141284 srt:MinimumMember asns:OtherWarrantMember 2024-09-30 0001141284 srt:MaximumMember asns:OtherWarrantMember 2024-09-30 0001141284 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001141284 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001141284 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001141284 us-gaap:RestrictedStockUnitsRSUMember us-gaap:WarrantMember 2024-09-30 0001141284 us-gaap:RestrictedStockUnitsRSUMember us-gaap:WarrantMember 2023-09-30 0001141284 srt:NorthAmericaMember 2024-01-01 2024-09-30 0001141284 srt:NorthAmericaMember 2023-01-01 2023-09-30 0001141284 srt:NorthAmericaMember 2024-07-01 2024-09-30 0001141284 srt:NorthAmericaMember 2023-07-01 2023-09-30 0001141284 srt:EuropeMember 2024-01-01 2024-09-30 0001141284 srt:EuropeMember 2023-01-01 2023-09-30 0001141284 srt:EuropeMember 2024-07-01 2024-09-30 0001141284 srt:EuropeMember 2023-07-01 2023-09-30 0001141284 srt:AsiaPacificMember 2024-01-01 2024-09-30 0001141284 srt:AsiaPacificMember 2023-01-01 2023-09-30 0001141284 srt:AsiaPacificMember 2024-07-01 2024-09-30 0001141284 srt:AsiaPacificMember 2023-07-01 2023-09-30 0001141284 asns:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001141284 asns:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001141284 asns:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001141284 asns:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001141284 asns:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001141284 asns:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001141284 asns:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001141284 asns:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001141284 asns:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001141284 asns:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001141284 asns:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001141284 asns:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS

Exhibit 31.1

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the

Securities Exchange Act of 1934

 

I, Tuvia Barlev, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Actelis Networks, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

  

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2024 By: /s/ Tuvia Barlev
    Tuvia Barlev
   

Chief Executive Officer

(Principal Executive Officer)

 


Exhibit 31.2

 

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the

Securities Exchange Act of 1934

 

I, Yoav Efron, certify that:

 

1 I have reviewed this Quarterly Report on Form 10-Q of Actelis Networks, Inc;
   
2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
    
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2024 By: /s/ Yoav Efron
    Yoav Efron
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Actelis Networks, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Tuvia Barlev, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Company’s Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

Date: November 14, 2024 By: /s/ Tuvia Barlev
    Tuvia Barlev
   

Chief Executive Officer

(Principal Executive Officer)

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Actelis Networks, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yoav Efron, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Company’s Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

  

Date: November 14, 2024 By: /s/ Yoav Efron
    Yoav Efron
   

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

v3.24.3
Cover - shares
9 Months Ended
Sep. 30, 2024
Nov. 14, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Entity Information [Line Items]    
Entity Registrant Name ACTELIS NETWORKS, INC.  
Entity Central Index Key 0001141284  
Entity File Number 001-41375  
Entity Tax Identification Number 52-2160309  
Entity Incorporation, State or Country Code DE  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 4039 Clipper Court  
Entity Address, City or Town Fremont  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94538  
Entity Phone Fax Numbers [Line Items]    
City Area Code (510)  
Local Phone Number 545-1045  
Entity Listings [Line Items]    
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ASNS  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   6,253,715
v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 2,241 $ 620
Short term deposits 197
Restricted cash equivalents 300 1,565
Trade receivables, net of allowance for credit losses of $168 as of September 30, 2024, and December 31, 2023. 1,828 664
Inventories 2,372 2,526
Prepaid expenses and other current assets, net of allowance for doubtful debts of $181 and $144 as of September 30, 2024, and December 31, 2023, respectively 481 340
TOTAL CURRENT ASSETS 7,222 5,912
NON-CURRENT ASSETS:    
Property and equipment, net 52 61
Prepaid expenses 592 592
Restricted cash and cash equivalents 3,330
Restricted bank deposits 91 94
Severance pay fund 200 238
Operating lease right of use assets 515 918
Long term deposits 78 78
TOTAL NON-CURRENT ASSETS 1,528 5,311
TOTAL ASSETS 8,750 11,223
CURRENT LIABILITIES:    
Credit line 927
Current maturities of long-term loans 1,335
Trade payables 893 1,769
Deferred revenues 277 389
Employee and employee-related obligations 760 737
Accrued royalties 1,033 1,062
Current maturities of operating lease liabilities 450 498
Other current liabilities 735 1,122
TOTAL CURRENT LIABILITIES 5,075 6,912
NON-CURRENT LIABILITIES:    
Long-term loan, net of current maturities 150 3,154
Deferred revenues 160 71
Operating lease liabilities 62 405
Accrued severance 226 270
Other long-term liabilities 16 23
TOTAL NON-CURRENT LIABILITIES 614 3,923
TOTAL LIABILITIES 5,689 10,835
COMMITMENTS AND CONTINGENCIES (Note 10)
MEZZANINE EQUITY    
Redeemable convertible preferred stock - $0.0001 par value, 10,000,000 authorized as of September 30, 2024, December 31, 2023. None issued and outstanding as of September 30, 2024, December 31, 2023.
WARRANTS TO PLACEMENT AGENT (Note 7) 228 159
SHAREHOLDERS' EQUITY :    
Common stock, value 1 1
Additional paid-in capital 45,095 39,916
Accumulated deficit (42,263) (39,688)
TOTAL SHAREHOLDERS’ EQUITY 2,833 229
TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY 8,750 11,223
Non-voting    
SHAREHOLDERS' EQUITY :    
Common stock, value
v3.24.3
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Trade receivables, net of allowance for credit losses (in Dollars) $ 168 $ 168
Prepaid expenses and other current assets, net of allowance for doubtful debts (in Dollars) $ 181 $ 144
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 30,000,000 30,000,000
Common stock, shares issued 6,254,664 3,007,745
Common stock, shares outstanding 6,254,664 3,007,745
Redeemable Convertible Preferred Stock    
Redeemable Convertible Preferred Stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Redeemable Convertible Preferred Stock, authorized 10,000,000 10,000,000
Redeemable Convertible Preferred Stock, issued
Redeemable Convertible Preferred Stock, outstanding
Non-voting    
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 2,803,774 2,803,774
Common stock, shares issued
Common stock, shares outstanding
v3.24.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
REVENUES $ 2,541 $ 845 $ 6,698 $ 4,589
COST OF REVENUES 798 619 2,792 3,043
GROSS PROFIT 1,743 226 3,906 1,546
OPERATING EXPENSES:        
Research and development expenses 543 691 1,793 2,117
Sales and marketing expenses 727 691 2,001 2,332
General and administrative expenses 790 971 2,398 2,805
Other income (163)
TOTAL OPERATING EXPENSES 2,060 2,353 6,029 7,254
OPERATING LOSS (317) (2,127) (2,123) (5,708)
Interest expense (246) (161) (590) (512)
Other Financial income, net 52 1,421 138 1,865
NET COMPREHENSIVE LOSS FOR THE PERIOD $ (511) $ (867) $ (2,575) $ (4,355)
Net loss per share attributable to common shareholders – basic (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
Net loss per share attributable to common shareholders – diluted (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
Weighted average number of common stocks used in computing net loss per share – basic (in Shares) 6,014,548 2,685,626 4,429,738 2,254,235
Weighted average number of common stocks used in computing net loss per share – diluted (in Shares) 6,014,548 2,685,626 4,429,738 2,254,235
v3.24.3
Consolidated Statements of Mezzanine Equity and Shareholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Redeemable Convertible Preferred Stock
Warrants To Placement Agent
Common Stock
Non-voting Common Stock
Additional paid-in capital
Accumulated deficit
Total
Balance at Dec. 31, 2022 $ 1 $ 36,666 $ (33,402) $ 3,265
Balance (in Shares) at Dec. 31, 2022     1,737,986      
Share based compensation 298 298
Share based compensation (in Shares)            
Repurchase of common stock [1] (50) (50)
Repurchase of common stock (in Shares)     (7,920)      
Issuance of common stock and pre-funded warrants upon private placement, net of underwriting commissions and other offering costs 104 [1] 1,356 1,356
Issuance of common stock and pre-funded warrants upon private placement, net of underwriting commissions and other offering costs (in Shares)     190,000        
Exercise of options into common stock [1] 10 10
Exercise of options into common stock (in Shares)     19,443        
Exercise of pre-funded warrants into common stock
Exercise of pre-funded warrants into common stock (in Shares)     754,670        
Reclassification of warrants from liabilities to equity 314 314
Net comprehensive loss for the period (4,355) (4,355)
Net comprehensive loss for the period (in Shares)            
Balance at Sep. 30, 2023 104 $ 1 38,594 (37,757) 838
Balance (in Shares) at Sep. 30, 2023     2,694,179      
Balance at Jun. 30, 2023 104 $ 1 38,174 (36,890) 1,285
Balance (in Shares) at Jun. 30, 2023     1,930,718      
Share based compensation 106 106
Exercise of options into common stock [1] [1] [1]
Exercise of options into common stock (in Shares)     8,791        
Exercise of Pre funded warrants into common stock (Note 7b) [1] [1]
Exercise of Pre funded warrants into common stock (Note 7b) (in Shares)     754,670        
Reclassification of warrants from liabilities to equity 314 314
Net comprehensive loss for the period (867) (867)
Balance at Sep. 30, 2023 104 $ 1 38,594 (37,757) 838
Balance (in Shares) at Sep. 30, 2023     2,694,179      
Balance at Dec. 31, 2023 159 $ 1 39,916 (39,688) $ 229
Balance (in Shares) at Dec. 31, 2023     3,007,745     3,007,745
Exercise of pre-funded warrants into common stock (in Shares)             970,187
Balance at Jun. 30, 2024 201 $ 1 42,687 (41,752) $ 936
Balance (in Shares) at Jun. 30, 2024     5,017,322      
Balance at Dec. 31, 2023 159 $ 1 39,916 (39,688) $ 229
Balance (in Shares) at Dec. 31, 2023     3,007,745     3,007,745
Share based compensation     259   $ 259
Vesting of RSUs
Vesting of RSUs (in Shares)     28,228 [1]      
Issuance of common stock, net of offering costs (note 7f)   [1] 316 316
Issuance of common stock, net of offering costs (note 7f) (in Shares)     227,939        
Exercise of options into common stock   [1] 32 $ 32
Exercise of options into common stock (in Shares)     21,225       21,225
Warrant to lender   61 $ 61
Exercise of Pre funded warrants into common stock (Note 7b)   [1]  
Exercise of Pre funded warrants into common stock (Note 7b) (in Shares) [1]     970,187        
Warrant inducement agreement, net of offering costs (Note 7e)   27 1,951 1,951
Warrant inducement agreement, net of offering costs (Note 7e) (in Shares) [1]     999,670        
Warrant inducement agreement, net of offering costs (Note 7d)   42 [1] 2,560 2,560
Warrant inducement agreement, net of offering costs (Note 7d) (in Shares)     999,670        
Net comprehensive loss for the period     (2,575) (2,575)
Balance at Sep. 30, 2024 228 $ 1 45,095 (42,263) $ 2,833
Balance (in Shares) at Sep. 30, 2024     6,254,664     6,254,664
Balance at Jun. 30, 2024 201 $ 1 42,687 (41,752) $ 936
Balance (in Shares) at Jun. 30, 2024     5,017,322      
Share based compensation         80   80
Vesting of RSUs    
Vesting of RSUs (in Shares) [1]     9,733        
Issuance of common stock, net of offering costs (note 7f)   [1]   316   316
Issuance of common stock, net of offering costs (note 7f) (in Shares)     227,939        
Warrant to lender     61   61
Warrant inducement agreement, net of offering costs (Note 7e)   27   1,951   1,951
Warrant inducement agreement, net of offering costs (Note 7e) (in Shares) [1]     999,670        
Net comprehensive loss for the period         (511) (511)
Balance at Sep. 30, 2024 $ 228 $ 1 $ 45,095 $ (42,263) $ 2,833
Balance (in Shares) at Sep. 30, 2024     6,254,664     6,254,664
[1] Represents an amount less than $1 thousand.
v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net comprehensive loss for the period $ (511) $ (867) $ (2,575) $ (4,355)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation     11 20  
Changes in fair value related to warrants to lenders and investors     (1,658)  
Warrant issuance costs     223  
Inventories write-downs 14 35 39 132  
Interest expenses     (56)  
Exchange rate differences     (58) (365)  
Share-based compensation     259 298  
Financial income from short and long term bank deposit     (11) (78)  
Changes in operating assets and liabilities:          
Trade receivables     (1,164) 2,319  
Net change in operating lease assets and liabilities     12 25  
Inventories     115 (1,651)  
Prepaid expenses and other current assets     (140) 62  
Long term prepaid expenses     (100)  
Trade payables     (875) 411  
Deferred revenues     (23) (262)  
Other current liabilities     (350) (185)  
Other long-term liabilities     35 (30)  
Net cash used in operating activities     (4,781) (5,194)  
CASH FLOWS FROM INVESTING ACTIVITIES:          
Short term deposits     198 1,363  
Long term Restricted bank deposits     75  
Long term deposits     (2)  
Purchase of property and equipment     (1) (6)  
Net cash provided by investing activities     197 1,430  
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of options     32 10  
Proceeds from issuance of common stocks, pre-funded warrants and warrants     [1] 3,500  
Proceeds from issuance common stock, net of offering costs     316  
Proceeds from credit lines with bank, net     927  
Proceeds from Warrant inducement agreement     5,248  
Underwriting discounts and commissions and other offering costs     (668) (291)  
Early repayment of long-term loan     (4,038)  
Repayment of long-term loan     (193) (583)  
Repurchase of common stock     (50)  
Net cash provided by financing activities     1,624 2,586  
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS     (14) (12)  
DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS     (2,974) (1,190)  
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD     5,515 4,279 $ 4,279
BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF THE PERIOD 2,541 3,089 2,541 3,089 5,515
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
Cash and cash equivalents 2,241 682 2,241 682 620
Restricted cash equivalents, current 300 300 1,565
Restricted cash and cash equivalents, non-current 2,407 2,407  
Total cash, cash equivalents and restricted cash $ 2,541 $ 3,089 2,541 3,089 $ 5,515
SUPPLEMENTARY DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid for interest     576 512  
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:          
Issuance costs of common stock, pre-funded warrants and warrants     104  
Reclassification of warrants from liability to equity upon amendment to private placement agreement     314  
Issuance costs of the Warrant inducement agreement     2,651  
Warrant to lender     $ 61  
[1] Represents an amount less than $1 thousand.
v3.24.3
General
9 Months Ended
Sep. 30, 2024
General [Abstract]  
GENERAL

NOTE 1 – GENERAL:

 

a.Actelis Networks, Inc. (hereafter -the Company) was established in 1998, under the laws of the state of Delaware. The Company has a wholly-owned subsidiary in Israel, Actelis Networks Israel Ltd. (hereafter – the Subsidiary). The Company is engaged in the design, development, manufacturing, and marketing of cyber hardened, hybrid fiber, networking solutions for IoT and Telecommunication governmental agencies and companies. The Company’s customers include governmental agencies, providers of telecommunication services, enterprises as well as resellers of the Company’s products. On May 12, 2022, the Company accepted a notification of effectiveness from the SEC, and on May 17, 2022, completed its IPO. The Company’s Common Stock is listed on the NASDAQ.

 

b.The Company has incurred significant losses and negative cash flows from operations. Net loss was $2,575 and $4,355 for the nine months ended September 30, 2024, and September 30, 2023, respectively. During the nine months ended September 30, 2024, and September 30, 2023, the Company had negative cash flows from operations of $4,781 and $5,194, respectively. As of September 30, 2024, the Company’s accumulated deficit was $42,263. The Company has funded its operations to date through equity and debt financing and has cash on hand (including restricted cash equivalents) of $2,541 restricted bank deposits of $91 as of September 30, 2024. The Company monitors its cash flow projections on a current basis and takes active measures to obtain the funding it requires to continue its operations. However, these cash flow projections are subject to various uncertainties concerning their fulfilment such as the ability to increase revenues by attracting and expanding its customer base or reducing cost structure. If the Company is not successful in generating sufficient cash flow or completing additional financing, including debt refinancing which shall release restricted cash, then it will need to execute a new cost reduction plan in addition to previous cost reduction plans that were executed so far. The Company’s transition to profitable operations is dependent on generating a level of revenue adequate to support its cost structure. The Company expects to fund operations using cash on hand, through operational cash flows and raising additional proceeds. There are no assurances, however, that the Company will be able to generate the revenue necessary to support its cost structure or that it will be successful in obtaining the level of financing necessary for its operations. Management has evaluated the significance of these conditions and has determined that the Company does not have sufficient resources to meet its operating obligations for at least one year from the issuance date of these condensed consolidated financial statements. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

 

c.On October 7, 2023, Hamas launched a series of attacks on civilian and military targets in Southern and Central Israel, to which the Israel Defense Forces have responded. In addition, both Hezbollah and the Houthi movement have attacked military and civilian targets in Northern Israel, to which Israel has responded, including through increased air and ground operations in Lebanon. In addition, the Houthi movement has attacked international shipping lanes in the red sea. Further, on April 2024, and on October 2024, Iran launched a series of drone and missile strikes against Israel, to which Israel has responded. To date our operations and financial results have not been materially affected. The Company continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments impacting its financial statements as appropriate, while supporting the safety and well-being of its employees. It is currently not possible to predict the effects of such conflicts and its impact on the Company’s business, operations or financial conditions. We continue to monitor political and military developments closely and examine the consequences for our business, results of operations and financial condition.

 

On November 21, 2023 we applied for an Israeli government grant associated with the Swords of Iron war declared by the State of Israel following the October 7, 2023 attack by Hamas.

 

The Company was found eligible and received an amount of $163 which was recognized as other income during the second quarter in 2024. The grant is not repayable.

 

d.On August 25, 2023, the Company received a notification letter from the Nasdaq Staff indicating that the company was not in compliance with Nasdaq Listing Rule 5550(b)(1) due to the company's failure to meet the Minimum Shareholders’ Equity Requirement or any alternatives to such requirement. In order to maintain listing on the Nasdaq Capital Market, the company has submitted a plan of compliance addressing how we intended to regain compliance. The company had until February 21, 2024 to evidence compliance with the Minimum Shareholders’ Equity Requirement.

 

On March 27, 2024, the Company received a delist determination letter (the “Delist Letter”) from the Staff advising the Company that the Staff had determined to delist the Company’s securities from Nasdaq due to its non-compliance with the Equity Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company timely requested a hearing before the Panel. Following the hearing, on June 10, 2024, the Panel granted the Company’s request for continued listing subject to the Company evidencing compliance with the Minimum Shareholders’ Equity Requirement by August 30, 2024.

 

On August 27, 2024, the Company received formal written notice from the Nasdaq Staff confirming that the Company has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550. In accordance with Nasdaq Listing Rule 5815(d)(4)(B), the Company will remain subject to Panel monitor for equity compliance through August 27, 2025.

v3.24.3
Significant Accounting Policies
9 Months Ended
Sep. 30, 2024
Significant Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:

 

a.Basis of presentation

 

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Article 10 of the Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States (“U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the 2024 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation.

 

b.Use of estimates in preparation of financial statements

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

 

c.Fair value of financial instruments

 

Fair value measurements are classified and disclosed in one of the following three categories:

 

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

 

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company measured the fair value of the warrants it issued (see note 5) based on Level 3 inputs, and the warrants liability amounted to $8 as September 30, 2024 and December 31, 2023, are presented in the Other current liabilities in the accompanying condensed consolidated balance sheets.

 

As of September 30, 2024, and December 31, 2023, the fair values of the Company’s cash and cash equivalents, restricted cash and cash equivalents, short and long-term deposits, trade receivables, trade payables, long-term loan, restricted bank deposits, Severance pay fund and other current assets approximated the carrying values of these instruments presented in the Company’s condensed consolidated balance sheets because of their nature.

 

d.Concentration of risk

 

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.

 

Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.

 

The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.

 

Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.

 

Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.

 

The Company has customers balances representing 10% or more of Trade receivables as follows:

  

 

1) 

Customer A represented 0% and 30% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

 

 

2) Customer B represented 4.5 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

 

3)

Customer C represented0 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

4)Customer D represented 38% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

5)Customer E represented 21.4% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

The Company does not see any credit risk regarding the major trade receivable balance.

 

New Accounting Pronouncements

 

Accounting Pronouncements effective in future periods

 

In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

v3.24.3
Inventories
9 Months Ended
Sep. 30, 2024
Inventories [Abstract]  
INVENTORIES

NOTE 3 – INVENTORIES:

 

   September 30,
2024
   December 31,
2023
 
Raw materials   1,344    757 
Finished goods   1,028    1,769 
    2,372    2,526 

 

Inventory write-downs amounted to $39 and $132 during the nine months ended September 30, 2024, and 2023, respectively and $14 and $35 during the three months ended September 30 2024 and 2023, respectively. Inventories write-downs are recorded in cost of revenues.

v3.24.3
Loans
9 Months Ended
Sep. 30, 2024
Loans [Abstract]  
LOANS

NOTE 4 – LOANS:

 

a.As a result of the COVID pandemic, the US and Israeli governments offered different programs of financial aid. The Company participated in the following programs:

 

On July 1, 2020, the Company received Economic Injury Disaster Loan (the “EIDL Loan”) from an American Bank under the Small Business Administration COVID19 Program in the total of $150. The loan matures in June, 2050 and bears interest of 3.75% per annum, payable monthly commencing on January 1, 2023, unless forgiven per program regulations. As of September 30, 2024, the total loan balance outstanding was $150. 

 

b.On December 9, 2020, the Company signed a new loan agreement with an Israeli based financial institution (“Migdalor”) for a loan of up to 20 million NIS ("New Israeli Shekel") (an amount of $6,000). The Company received $3,000 on December 2020, and additional $2,000 in January 2021. The loan bears interest of 9.6% per annum. The interest shall first be paid in 12 payments starting February 1, 2021. Starting February 1, 2022, the loan principal and interest shall be repaid in 72 equal payments, plus a one-time interest payment after the 36th month.

 

As part of the loan agreement, the Company issued the New Lender warrants to acquire common stock in the amount of $1,500.

 

In November 2021, the Company received additional funding in the amount of $1,000 from Migdalor. The loan bears interest of 9.6% per annum. Starting February 1, 2022, the loan principal and interest shall be repaid in 72 equal monthly payments, plus a onetime interest payment after the 24th month. The Company increased the value of the warrant issued to Migdalor to $1,800. Upon the consummation of the IPO, the Company converted all the above outstanding warrants issued to Migdalor into the Company’s common stock based on the contractual terms and conditions of the related warrant agreements.

 

The loan covenants (the “covenants”) include a debt to EBITDA minimum ratio or a coverage ratio of the loan by current assets.

   

On December 21, 2022, pursuant to the terms of the loan agreement, the Company deposited $2,000   to a Company-owned interest-bearing bank account, or the “designated account” (as defined in the agreement), to satisfy the required obligation associated with the loan agreement. An additional $2,000 was deposited in the designated account during the year ended December 31, 2023, which was classified in Restricted cash equivalents in the condensed Consolidated Balance Sheet.

 

As of September 30, 2024, the Company was in compliance with the covenants   of the Migdalor loan.

 

In February 2024, the Company performed a partial early repayment of Migdalor Loan in the amount of 2 million NIS (approximately $550). During April and May 2024, the Company made an additional partial early repayment of Migdalor loan in the amount of 10.9 million NIS approximately $2,933). In May 2024, the Company signed an amendment to the agreement with Migdalor, pursuant to which the remaining $470 of the one-time interest payment which was originally due in January 2024 to Migdalor will be paid in 12 equal monthly payments bearing 9.6% interest from February 2024 till February 2025. In addition, the Company is obligated to issue Migdalor warrants to acquire common stock for up to $150 subject to the agreed upon formula. The Company has a paid, during July 2024, a total amount of $196 (for the periods from February to June) of the one-time interest payment.

 

In July 2024, the company repaid the remaining loan balance to Migdalor, totaling 1.16 million ILS (approximately 0.3$ million )

 

As of September 30, 2024, the total outstanding of the one-time interest payment was 0.7 million NIS (approximately $0.2 million).

 

c.On January 15, 2024, the Subsidiary entered into a credit agreement with Bank Mizrahi-Tefahot. The Credit Agreement provides for a $1,500 credit facility available to be used by the Subsidiary (“New Credit Line”). Under the New Credit Line, which will be secured by the Subsidiary’s customer receivables, the Subsidiary will pay an annual fixed interest at a Federal SOFR rate plus 5.5% on any amount withdrawn under the New Credit Line. The New Credit Line, at an annual fixed interest rate of 1.5% for unused credit amount, expires on December 27, 2024, subject to extension.

 

Under the Credit Agreement, the Company is permitted to draw upon the New Credit Line for customer invoices that meet the following conditions:

 

(a)Throughout the duration of the New Credit Line, the Company may present customer receivables and receive credit financing that does not exceed 80% of the aggregate amount of the open customer invoices securing the New Credit Facility; The credit financing is to be repaid within 90 days.

 

(b)Customer invoices are payable within 90 days from the date of the Company’s monthly report to the Lender; and

 

(c)No single customer of the Company may account for open customer invoices securing over 30% of the total borrowed amount under the New Credit Line.

 

The Credit Line balance drawn will be examined every month and adjusted up to every three months and Repayment of the Credit Line will be made up to every three months subject to the expiration of the financing period for the invoices that were financed. The Company may refinance newly issued invoices at any time up to the Credit Line limit and subject to the terms of the Credit Line.

 

As of September 30, 2024, the Subsidiary used $0.9 million of the credit line. 

v3.24.3
Warrants
9 Months Ended
Sep. 30, 2024
Warrants [Abstract]  
WARRANTS

NOTE 5 – WARRANTS:

 

The company has several types of warrants. The warrants classified as liability are presented in this note, and the equity warrants are presented under note 7. 

 

a.On August 24, 2016, the Company issued warrants to Comerica Bank (“Comerica”) for the purchase of 7,305 shares of the Company’s Series B Redeemable Preferred Stock at an exercise price of $10.2672 per share contemporaneously with obtaining a loan from Comerica which was fully repaid in 2018 (the “Comerica Warrants”). The Comerica Warrants are exercisable at any time during the contract period which ends on August 24, 2026.

 

Additionally, in connection with the consummation of the IPO which occurred in May 2022, and the change of the type of the stock from redeemable preferred stock to common stock at conversion, the Company reassessed the Comerica Warrants. As part of the contractual terms and conditions of Comerica’s Warrants, a portion of the warrants are exercisable, as of the IPO date, into the Company’s common stock.

 

The Company has evaluated whether the Comerica Warrants are still classified as liabilities and concluded that due to a change-of-control provision which may affect the exercise price or entitle Comerica to demand cash, instead of shares, to settle the warrants, Comerica’s Warrants will continue to be classified as liabilities and will be exercisable into the Company’s common shares. The Comerica Warrants are still outstanding as of September 30, 2024.

 

b.On May 8, 2023, the Company completed a fund-raising round. Upon the consummation of the Offering and pursuant to an agreement entered into with the Holder and the underwriter, the Company issued warrants to purchase shares of Common Stock. Such warrants were classified as liabilities based on the terms of the underlying agreement. On September 30, 2023, these warrants were reclassified to equity due to an amendment to the warrants’ agreements (for further details see also Note 7b). On June 6, 2024, these warrants were exercised pursuant to the inducement agreement, as described in notes 7d below.
v3.24.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2024
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 6 – COMMITMENTS AND CONTINGENCIES:

 

The Company is obligated to repay certain research and development grants received from the Government of Israel in the form of a royalty rate on future sales of products derived from the funded research and development activities. The aggregate amount of royalties to be paid is determined based on 100% of the total grants received for qualified projects plus interest. The Company may be required to pay royalties based on previous years funding in periods after September 30, 2024, for the future sale of product that includes technology developed and funded with these research and development grants received to date.

 

As of September 30, 2024, the Company had received approximately $14,300 (approximately $15,830 including interest) and repaid approximately $10,518 in such grants.

 

As of September 30, 2024, and December 31, 2023, the Company had a liability to pay royalties in the amount of approximately $1,033 thousands and $1,062 thousands respectively.

v3.24.3
Shareholders’ Equity
9 Months Ended
Sep. 30, 2024
Shareholders’ Equity [Abstract]  
SHAREHOLDERS’ EQUITY

NOTE 7 – SHAREHOLDERS’ EQUITY:

 

a.During January and February 2023, the Company purchased 7,920 shares of its common stock, for a total price of $50. (Total of 10,690 common stock are held by the company as treasury shares).

 

b.Offering of common stocks and warrants May 2023:

 

On May 8, 2023, the Company completed a fund-raising round in a total gross amount of $3,500 pursuant to which the Company agreed to issue and sell to Armistice Capital Master Fund Ltd. (the “Holder”) in a private placement (the “Offering”):

 

1.190,000 shares of the Company’s common stock, $0.0001 par value;

 

2.754,670 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 754,670 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement. The warrants were classified as equity pursuant to ASC 815-40. During July and August 2023, the Holder elected to exercise 754,670 of the pre-funded warrant. The total exercise price in the amount of $0.0755 was paid in cash.

 

3.warrants to purchase up to 944,670 shares of Common Stock (“Common Warrants”) for an exercise price of $3.58 which are exercisable (physically or upon occurrence of certain events on net-cash basis at the Holder’s discretion) immediately upon their issuance until November 8, 2028. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

The Company determined that the Common Warrants are not indexed to the Company’s own stock and therefore are precluded from equity classification. The Common Warrants will be measured at fair value at inception and in subsequent reporting periods with changes in fair value recognized as financial income or expense as change in fair value of warrant liabilities in the period of change in the condensed consolidated statements of comprehensive loss.

 

The Common Warrants were recorded at fair value on May 8, 2023, at $1,972 and were classified as a long-term liability on the Condensed Consolidated Balance Sheet, and the residual value allocated to the common stock and pre-funded warrants which were classified as equity.

 

On September 30, 2023, the Company and the Holder entered into a Common warrants amendment agreement (the “Amendment”) to amend the Common warrants to purchase up to 944,670 shares of the Company’s common stock, par value $0.0001 issued to the Holder. The Amendment made certain adjustments to the definition of a “Fundamental Transaction” in Common Warrant agreement. Additionally, the Amendment increased the number of Common Warrants to include an additional 55,000 Common warrants and changed the exercise price of the Common Warrants to $2.75.

 

The Company reclassified the Common warrants as equity based on the guidance provided under ASC 815-40, due to the adjustments stated in the amendment. As of the date of the amendment of the Common warrants, the fair value of the warrants was estimated at $314.

 

Offering Costs related to May 2023 fund-raising round

 

Upon the consummation of the Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $291. The Company has also granted to the Underwriter upon the consummation of the Offering, warrants to purchase up to 66,127 of the Company’s common stocks which carry the same terms as the common stock warrants, except for the exercise price which reflect 125% of the share price in the Offering ($4.6313). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $104.

 

c.Offering of common stocks and warrants December 2023

 

On December 20, 2023, the Company completed a fund-raising round in a total gross amount of $1,500 pursuant to which the Company agreed to issue and sell to the Holder in December’s private placement (the “Second Offering”):

 

1)301,000 shares of the Company’s common stock, $0.0001 par value;

 

2)970,187 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 970,187 shares of Common Stock for an exercise price of $0.0001 which are exercisable (either physically or on a net-cash basis at the Holder’s discretion) immediately upon their issuance until their full exercise. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also has certain rights upon a fundamental transaction (as defined in the agreement) as specified in the agreement. During June 2024, the Holder elected to exercise 970,187 of the pre-funded warrant. The total exercise price in the amount of $0.097 was paid in cash.

 

d.Warrant Inducement Agreement June 2024:

 

3)warrants to purchase up to 1,271,187 shares of Common Stock (“Common Warrants”) for an exercise price of $1.18 which are exercisable (physically or upon occurrence of certain events on a net-cash basis at the Holder’s discretion) immediately upon their issuance until June 20, 2029. Their exercise price is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement). 

 

In connection with the Second Offering, the Company also has agreed to amend the existing warrants to purchase up to an aggregate of 999,670 shares of the Company’s common stock that were previously issued in May 2023 (and amended in September 2023) at an exercise price of $2.75 per share, such that effective on the date of shareholder approval to amend the warrants, the amended warrants will have a reduced exercise price of $1.18 per share. In the event that the Shareholder Approval is not obtained, the warrant amendment shall be null and void and the provisions of the existing warrants shall remain unchanged. The shareholder approval was not obtained until June 5, 2024, when the Company entered into a warrant inducement agreement with the Holder. See note 7(d) for further details.

 

The common stock, pre-funded warrants and the warrants were classified as equity pursuant to ASC 815-40.

 

Offering Costs related to December 2023 fund-raising

 

Upon the consummation of the Second Offering and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $129. The Company has also granted to the Underwriter upon the consummation of the Second Offering, warrants to purchase up to 88,983 of the Company’s common stocks which carry the same terms as the common stock warrants described above (Note 7b.), except for the exercise price which reflect 125% of the share price in the Second Offering ($1.475). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $55. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 57%, a risk-free rate of 3.86%, a contractual term of 5.5 years and a stock price at the issuance date of 1.18.

 

The total Second Offering costs in the amount of $230 was recognized in equity.

 

On June 5, 2024, the Company entered into a warrant inducement agreement with the Holder (as defined in Note 7b above) regarding the Common Warrants to purchase up to an aggregate of 999,670 shared of the Company’s common stock originally issued on May 8, 2023 at an exercise price of $2.75 per share (the “Existing Warrants”).

 

Pursuant to the inducement agreement, the Holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.75 per share in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “June Warrants”) for an exercise price of 2.00$ at a 1:1 exchange ratio.

 

As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.

 

The June Warrants will be exercisable immediately upon issuance, half of which with a term of 5.5 years (the “5.5 Years June Warrants”), and the remaining with a term of 2 years (the “2 Years June Warrants”) (physically or upon occurrence of certain events on a cashless basis at the Holder’s discretion). Their exercise price and the number of shares issuable upon exercise is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

Pursuant to the inducement agreement the Holder exercised the Existing Warrants for a total gross cash amount of approximately $2,999, before deducting offering costs.

 

As of the issuance date of the June Warrants, the fair value of the warrants was estimated at $1,451. The Company valuation was based using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:

 

   5.5 Years
June
Warrants
   2 Years
June
Warrants
 
Term   5.5 years    2 years 
Expected volatility   44.77%   44.77%
Risk-free rate   3.95%   4.28%
Stock price  $1.97   $1.97 

 

In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the Induced Warrants was accounted for as an additional equity issuance cost for the warrant inducement, which was recorded to additional paid-in capital. On June 30, 2024, the Company entered into a warrant inducement agreement with the Holder. See note 7(e) for further details.

 

Offering Costs related to warrant inducement agreement June 2024:

 

Upon the consummation of the to the warrant inducement agreement and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of 331$ and has paid other related issuance cost amounting to approximately $66. The Company has also granted to the Underwriter upon the consummation of the warrant inducement, warrants to purchase up to 69,977 of the Company’s common stocks which carry the same terms as the June Warrants described above, except for the exercise price which reflect 125% of the reduced exercise price of the Existing Warrants ($3.4375). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $42. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 44.77% a risk-free rate of 3.95% contractual term of 5.5 years, and a stock price at the issuance date of $1.97.

 

The total offering costs (including the inducement effects) in the amount of approximately $1,890 was recognized in equity.

 

e.Warrant Inducement Agreement July 2024:

 

On June 30, 2024, the Company entered into a warrant inducement agreement with Holder (as defined in Note 7b above), to purchase up to an aggregate of 999,670 shares of the 2 Years June Warrants, originally issued on June 6, 2024 at an exercise price of $2.00 per share (the “2 Years June Warrants”). The closing date of the June 30, 2024 Inducement Letter Agreement was on July 2, 2024.

 

Pursuant to the inducement agreement, the holder agreed to exercise for cash the 2 Years June Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.00 per share, in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “July Warrants”), for an exercise price of $1.75 at a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $250.

 

The July Warrants will be exercisable immediately upon issuance, with a term of 2 years.

 

Their exercise price and the number of shares issuable upon exercise is adjustable upon dilutive events (such as subsequent rights offerings, pro-rata distributions and stock dividends and splits). The Holder also possesses a right to receive any additional consideration that holders of common stocks may be entitled to upon a fundamental transaction (as defined in the agreement).

 

Pursuant to the inducement agreement the Holder exercised the 2 Years June Warrants for a total gross cash amount of approximately $2,249, before deducting offering costs.

 

As of the issuance date of the July Warrants, the fair value of the warrants was estimated at $1,131. The Company valuation was based using the Black-Scholes valuation model. The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:

 

   2 Years
June
Warrants
 
Term   2 years 
Expected volatility   61.60%
Risk-free rate   4.28%
Stock price  $1.65 

 

In accordance with ASC Topic 815 guidance on equity classified warrant modifications, the incremental change in fair value of the induced warrants was accounted for as an additional equity issuance cost for the warrant inducement, which was recorded to additional paid-in capital. These warrants have not been exercised as of September 30, 2024.

 

Offering Costs related to warrant inducement agreement July 2024:

 

Upon the consummation of the to the warrant inducement agreement and pursuant to an agreement entered into with H.C. Wainwright & Co., LLC (the “Underwriter”), the Company has paid in cash to the Underwriter (and the escrow agent) a total amount of $271. The Company has also granted to the Underwriter upon the consummation of the warrant inducement, warrants to purchase up to 69,977 of the Company’s common stocks which carry the same terms as the July Warrants described above, except for the exercise price which reflect 125% of the reduced exercise price of the June Warrants ($2.50). The warrants are classified as mezzanine equity based on the guidance provided under ASC 480-10-S99-3A and SAB Topic 14. E.

 

As of the issuance date of the underwriter warrants, the fair value of the warrants was estimated at $27. The valuation was based on a Black-Scholes option-pricing model, using an expected volatility of 61.60% a risk-free rate of 3.86% contractual term of 2 years, respectively, and a stock price at the issuance date of 1.65$.

 

The total offering costs (including the inducement effects) in the amount of approximately $1,429 was recognized in equity.

 

Total outstanding warrants as of 30 September,2024, are as follow:

 

    Number of warrants   Exercise
price
   Period left in years 
Warrants May 2023    66,127    $4.625    4.15 
Warrants December 2023    1,360,170    $1.18 - $1.47    4.75 

Warrants June 2024

    1,069,647    $2.0 – $3.43    5.25 
Warrants July 2024    2,069,317    $2.5-$1.75    2.0 
Other    36,792    $10.27 - $50    1.75 – 2.65 
Outstanding as of September 30, 2024    4,602,053           

 

f.At the Market Offering Agreement:

 

On September 18, 2024, the Company entered into At the Market Offering Agreement (the “ATM Agreement”), with H.C. Wainwright & Co. (“Wainwright”), as sales agent, pursuant to which the Company may issue and sell shares of its common stock, from time to time, through Wainwright.

 

Under the ATM Agreement, Wainwright may sell shares in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, as amended, or in any other method permitted by law, including in privately negotiated transactions.

 

The Company or Wainwright may suspend or terminate the ATM Agreement upon notice to the other party and subject to other conditions.

 

The Company will pay Wainwright a commission of 3.0% of the gross sales price of any common stock sold under the ATM Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company will also reimburse Wainwright for certain specified expenses.

 

On September 25, 2024, in connection with the execution of the ATM Agreement, the Company filed with the SEC a prospectus supplement (the “Prospectus Supplement”) to the base prospectus contained in the 2024 Shelf Registration Statement, which Prospectus Supplement related to the offering of up to $3.4 million of shares of the Company’s common stock under the ATM Agreement.

 

Subsequent to entering into the ATM Agreement, the Company issued and sold 227,939 shares of common stock for gross proceeds of approximately $328.

 

g.Share-based compensation:

 

1)A summary of the Company's share options, granted to employees, directors, under option plans is as follows:

 

    Number of options   Weighted Average Exercise
Price
   Weighted Average Remaining Contractual Life 
Outstanding – January 1, 2024    87,764   $3.63    4.11 
Granted    
-
    
-
    - 
Exercised    (21,225)  $3.37                  - 
Forfeited    (1,159)  $16.5    - 
                 
Outstanding - September 30, 2024    65,380   $9.81    3.4 
Exercisable - September 30, 2024    60,799   $9.81    2.7 

 

The majority of the Share-based compensation expenses included in the Condensed consolidated statements of comprehensive under General and Administrative.

 

2)A summary of the Company's RSUs, granted to employees, directors, under option plans is as follows:

 

   September 30 2024 
   Number of RSUs   Weighted-Average Grant Date Fair Value 
RSUs outstanding at the beginning of the year   71,280   $10.35 
Granted during the period   
-
    
-
 
Vested during the period   (28,228)  $3.79 
Forfeited during the period   (6,798)  $6.35 
Outstanding as of September 30, 2024   36,254   $6.15 

 

The majority of the RSUs expenses included in the Condensed consolidated statements of comprehensive under General and Administrative.

v3.24.3
Basic and Diluted Loss Per Share
9 Months Ended
Sep. 30, 2024
Basic and Diluted Loss Per Share [Abstract]  
BASIC AND DILUTED LOSS PER SHARE

NOTE 8 – BASIC AND DILUTED LOSS PER SHARE:

 

Basic net loss per share is computed using the weighted average number of shares of common stock and pre-funded warrants and fully vested RSUs outstanding during the period, net of treasury shares. In computing diluted loss per share, basic loss per share is adjusted to take into account the potential dilution that could occur upon the exercise of options and RSUs granted under employee stock compensation plans, and the exercise of warrants using the treasury stock method.

 

Diluted loss per share excludes 4,602,053 shares underlying outstanding warrants, 65,380 shares underlying outstanding options, and 36,254 shares underlying outstanding RSUs for the three and nine months ended September 30, 2024, because the effect of their inclusion in the computation would be antidilutive.

 

Diluted loss per share excludes 1,047,589 shares underlying outstanding warrants, 90,377 shares underlying outstanding options, and 72,945 shares underlying outstanding RSUs for the three and nine months ended September 30, 2023, because the effect of their inclusion in the computation would be antidilutive.

 

The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:

 

   Three months ended
September 30,
   Nine months ended
September 30,
 
   2024   2023   2024   2023 
Numerator:                
                 
Net loss  $(511)  $(867)  $(2,575)  $(4,355)
                     
Denominator:                    
                     
Common shares outstanding used in computing net loss per share attributable to common shareholders   6,014,548    2,389,296    3,782,947    1,998,123 
                     
Pre-Funded warrants to purchase common shares   
-
    304,250    646,791    262,712 
                     
Repurchase of common stock   
-
    (7,920)   
-
    (6,600)
                     
Weighted average number of shares used in computing basic and diluted net loss per share attributable to common shareholders   

6,014,548

    2,685,626    4,429,738    2,254,235 
Net loss per share attributable to common shareholders – basic and diluted  $(0.09)  $(0.32)  $(0.59)  $(1.93)
v3.24.3
Revenues
9 Months Ended
Sep. 30, 2024
Revenues [Abstract]  
REVENUES

NOTE 9 – REVENUES:

 

The Company operates as one operating segment (developing and marketing access broadband equipment for copper and fiber networks).

 

a.Geographic information:

 

Following is a summary of revenues by geographic areas. Revenues attributed to geographic areas, based on the location of the end customers:

 

   Nine months ended
September 30,
   Three months ended
September 30,
 
   2024   2023   2024   2023 
North America   5,316   $1,863    1,854   $454 
Europe, the Middle East and Africa   1,282    2,274    614    371 
Asia Pacific   100    452    73    20 
    6,698   $4,589   $2,541   $845 

 

b.Revenues from contract liability:

 

    Nine months ended,
September 30,
2024
    Year ended,
December 31,
2023
 
Opening balance     460       648  
Revenue recognized that was included in the contract liability balance at the beginning of the year     (607 )     (544 )
Additions     584       356  
Remaining performance obligations     437       460  

 

As of September 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligation is $437, and the Company will recognize this revenue over the next 51 months.

 

c.Customers representing 10% or more of net revenues and the amount of revenues recognized are as follows:

 

   Three months ended
September 30, 2024
   Nine months ended
September 30, 2024
 
Customer A   45%  $1,143    18%  $1,205 
Customer B   2%  $51    34%  $2,227 
Customer C   10%  $254    6%  $401 

 

   Three months ended
September 30, 2023
   Nine months ended
September 30, 2023
 
Customer A   2%  $20    20%  $920 
Customer B   24%  $201    11%  $510 
Customer C   2%  $20    10%  $469 
Customer D   10%  $80    4%  $171 

 

The majority of the Company's revenues are recognized at a point in time.

v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net Income (Loss) $ (511) $ (867) $ (2,575) $ (4,355)
v3.24.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2024
Significant Accounting Policies [Abstract]  
Basis of presentation
a.Basis of presentation

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with Article 10 of the Securities and Exchange Commission (“SEC”)’s Regulation S-X. As permitted under those rules, certain footnotes and other financial information that are normally required by generally accepted accounting principles in the United States (“U.S. GAAP”) can be condensed or omitted. These financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of its financial position as of and for the periods presented. These condensed consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2023. The results of operations for the three and nine months ended September 30, 2024, are not necessarily indicative of results that could be expected for the 2024 fiscal year or any other interim period or for any other future year. All intercompany transactions and balances have been eliminated in consolidation.

Use of estimates in preparation of financial statements
b.Use of estimates in preparation of financial statements

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

 

Fair value of financial instruments
c.Fair value of financial instruments

Fair value measurements are classified and disclosed in one of the following three categories:

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 – Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company measured the fair value of the warrants it issued (see note 5) based on Level 3 inputs, and the warrants liability amounted to $8 as September 30, 2024 and December 31, 2023, are presented in the Other current liabilities in the accompanying condensed consolidated balance sheets.

As of September 30, 2024, and December 31, 2023, the fair values of the Company’s cash and cash equivalents, restricted cash and cash equivalents, short and long-term deposits, trade receivables, trade payables, long-term loan, restricted bank deposits, Severance pay fund and other current assets approximated the carrying values of these instruments presented in the Company’s condensed consolidated balance sheets because of their nature.

Concentration of risk
d.Concentration of risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and trade receivables. Cash and cash equivalents and restricted cash are placed with banks and financial institutions in the United States and Israel.

Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.

The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.

Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the condensed consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.

Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.

 

The Company has customers balances representing 10% or more of Trade receivables as follows:

 

1) 

Customer A represented 0% and 30% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

 

 

2) Customer B represented 4.5 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.
 

3)

Customer C represented0 % and 11% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

4)Customer D represented 38% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.
5)Customer E represented 21.4% and 0% of the Company Trade receivables balance as of September 30, 2024, and December 31, 2023, respectively.

The Company does not see any credit risk regarding the major trade receivable balance.

New Accounting pronouncements

New Accounting Pronouncements

Accounting Pronouncements effective in future periods

In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The ASU improves reportable segments disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09 Improvements to Income Tax Disclosures. The ASU improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this guidance on its consolidated financial statements.

v3.24.3
Inventories (Tables)
9 Months Ended
Sep. 30, 2024
Inventories [Abstract]  
Schedule of Inventories
   September 30,
2024
   December 31,
2023
 
Raw materials   1,344    757 
Finished goods   1,028    1,769 
    2,372    2,526 
v3.24.3
Shareholders’ Equity (Tables)
9 Months Ended
Sep. 30, 2024
Shareholders’ Equity [Abstract]  
Schedule of Significant Inputs into the Black-Scholes Valuation Model The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:
   5.5 Years
June
Warrants
   2 Years
June
Warrants
 
Term   5.5 years    2 years 
Expected volatility   44.77%   44.77%
Risk-free rate   3.95%   4.28%
Stock price  $1.97   $1.97 
The significant inputs into the Black-Scholes valuation model at the initial recognition date are as follows:
   2 Years
June
Warrants
 
Term   2 years 
Expected volatility   61.60%
Risk-free rate   4.28%
Stock price  $1.65 

 

Schedule of Total Outstanding Warrant Total outstanding warrants as of 30 September,2024, are as follow:
    Number of warrants   Exercise
price
   Period left in years 
Warrants May 2023    66,127    $4.625    4.15 
Warrants December 2023    1,360,170    $1.18 - $1.47    4.75 

Warrants June 2024

    1,069,647    $2.0 – $3.43    5.25 
Warrants July 2024    2,069,317    $2.5-$1.75    2.0 
Other    36,792    $10.27 - $50    1.75 – 2.65 
Outstanding as of September 30, 2024    4,602,053           
Schedule of Share Options, Granted to Employees, Directors, Under Option Plans A summary of the Company's share options, granted to employees, directors, under option plans is as follows:
    Number of options   Weighted Average Exercise
Price
   Weighted Average Remaining Contractual Life 
Outstanding – January 1, 2024    87,764   $3.63    4.11 
Granted    
-
    
-
    - 
Exercised    (21,225)  $3.37                  - 
Forfeited    (1,159)  $16.5    - 
                 
Outstanding - September 30, 2024    65,380   $9.81    3.4 
Exercisable - September 30, 2024    60,799   $9.81    2.7 
Schedule of Rsus, Granted to Employees, Directors, Under Option Plans A summary of the Company's RSUs, granted to employees, directors, under option plans is as follows:
   September 30 2024 
   Number of RSUs   Weighted-Average Grant Date Fair Value 
RSUs outstanding at the beginning of the year   71,280   $10.35 
Granted during the period   
-
    
-
 
Vested during the period   (28,228)  $3.79 
Forfeited during the period   (6,798)  $6.35 
Outstanding as of September 30, 2024   36,254   $6.15 
v3.24.3
Basic and Diluted Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2024
Basic and Diluted Loss Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:
   Three months ended
September 30,
   Nine months ended
September 30,
 
   2024   2023   2024   2023 
Numerator:                
                 
Net loss  $(511)  $(867)  $(2,575)  $(4,355)
                     
Denominator:                    
                     
Common shares outstanding used in computing net loss per share attributable to common shareholders   6,014,548    2,389,296    3,782,947    1,998,123 
                     
Pre-Funded warrants to purchase common shares   
-
    304,250    646,791    262,712 
                     
Repurchase of common stock   
-
    (7,920)   
-
    (6,600)
                     
Weighted average number of shares used in computing basic and diluted net loss per share attributable to common shareholders   

6,014,548

    2,685,626    4,429,738    2,254,235 
Net loss per share attributable to common shareholders – basic and diluted  $(0.09)  $(0.32)  $(0.59)  $(1.93)
v3.24.3
Revenues (Tables)
9 Months Ended
Sep. 30, 2024
Revenues [Abstract]  
Schedule of Revenues by Geographic Areas Following is a summary of revenues by geographic areas. Revenues attributed to geographic areas, based on the location of the end customers:
   Nine months ended
September 30,
   Three months ended
September 30,
 
   2024   2023   2024   2023 
North America   5,316   $1,863    1,854   $454 
Europe, the Middle East and Africa   1,282    2,274    614    371 
Asia Pacific   100    452    73    20 
    6,698   $4,589   $2,541   $845 
Schedule of Revenues from Contract Liability Revenues from contract liability:
    Nine months ended,
September 30,
2024
    Year ended,
December 31,
2023
 
Opening balance     460       648  
Revenue recognized that was included in the contract liability balance at the beginning of the year     (607 )     (544 )
Additions     584       356  
Remaining performance obligations     437       460  
Schedule of Revenues Recognized Customers representing 10% or more of net revenues and the amount of revenues recognized are as follows:
   Three months ended
September 30, 2024
   Nine months ended
September 30, 2024
 
Customer A   45%  $1,143    18%  $1,205 
Customer B   2%  $51    34%  $2,227 
Customer C   10%  $254    6%  $401 
   Three months ended
September 30, 2023
   Nine months ended
September 30, 2023
 
Customer A   2%  $20    20%  $920 
Customer B   24%  $201    11%  $510 
Customer C   2%  $20    10%  $469 
Customer D   10%  $80    4%  $171 
v3.24.3
General (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
General [Abstract]          
NET COMPREHENSIVE LOSS FOR THE PERIOD $ (511) $ (867) $ (2,575) $ (4,355)  
Cash flows from operations     (4,781) $ (5,194)  
Accumulated deficit (42,263)   (42,263)   $ (39,688)
Cash 2,541   2,541    
Restricted cash $ 91   91    
Other income     $ 163    
v3.24.3
Significant Accounting Policies (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Significant Accounting Policies [Line Items]      
Warrants liability (in Dollars) $ (1,658)  
Level 3 inputs [Member]      
Significant Accounting Policies [Line Items]      
Warrants liability (in Dollars) $ 8   $ 8
Customer Concentration Risk [Member] | Customer A [Member] | Trade Recievable [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk percentage 0.00%   30.00%
Customer Concentration Risk [Member] | Customer B [Member] | Trade Recievable [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk percentage 4.50%   11.00%
Customer Concentration Risk [Member] | Customer C [Member] | Trade Recievable [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk percentage 0.00%   11.00%
Customer Concentration Risk [Member] | Customer D [Member] | Trade Recievable [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk percentage 38.00%   0.00%
Customer Concentration Risk [Member] | Customer E [Member] | Trade Recievable [Member]      
Significant Accounting Policies [Line Items]      
Concentration risk percentage 21.40%   0.00%
v3.24.3
Inventories (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Inventories [Abstract]        
Inventory write-downs $ 14 $ 35 $ 39 $ 132
v3.24.3
Inventories (Details) - Schedule of Inventories - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Inventories [Abstract]    
Raw materials $ 1,344 $ 757
Finished goods 1,028 1,769
Total $ 2,372 $ 2,526
v3.24.3
Loans (Details)
₪ in Thousands, $ in Thousands
1 Months Ended 9 Months Ended
Feb. 29, 2024
USD ($)
Jan. 15, 2024
USD ($)
Jul. 31, 2024
USD ($)
Jul. 31, 2024
ILS (₪)
May 31, 2024
USD ($)
May 31, 2024
ILS (₪)
Apr. 30, 2024
USD ($)
Apr. 30, 2024
ILS (₪)
Feb. 29, 2024
USD ($)
Feb. 29, 2024
ILS (₪)
Nov. 30, 2021
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2024
ILS (₪)
Dec. 31, 2023
USD ($)
Dec. 21, 2022
USD ($)
Jan. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 09, 2020
USD ($)
Dec. 09, 2020
ILS (₪)
Jul. 01, 2020
USD ($)
Loans [Line Items]                                        
Bear interest, percentage                     9.60% 9.60% 9.60%              
Loan amount                                   $ 6,000 ₪ 20,000  
Received loan                               $ 2,000 $ 3,000      
Common stock, value                       $ 1   $ 1            
Received additional funding                     $ 1,000                  
Increased value of new lender warrant                       1,800                
Loan agreement                             $ 2,000          
Additional deposited                           2,000            
Repayment of new loan     $ 300 ₪ 1,160 $ 2,933 ₪ 10,900 $ 2,933 ₪ 10,900 $ 550 ₪ 2,000                    
Bearing interest percentage 9.60%               9.60% 9.60%                    
Warrant to acquire common stock amount $ 150                                      
Interest payment     $ 196                                  
Interest bonus outstanding                       $ 200 ₪ 700              
Credit facility, interest rate   1.50%                   30.00%                
Credit line                       $ 927              
Migdalor Loan [Member]                                        
Loans [Line Items]                                        
Interest payment         $ 470                              
Federal SOFR Rate [Member]                                        
Loans [Line Items]                                        
Credit facility, interest rate   5.50%                                    
EIDL Loan [Member]                                        
Loans [Line Items]                                        
Bear interest, percentage                                       3.75%
Total loan balance outstanding                       $ 150                
New Credit Facility [Member]                                        
Loans [Line Items]                                        
Credit facility, interest rate                       80.00%                
Credit financing repaid term                       90 days                
Common Stock [Member]                                        
Loans [Line Items]                                        
Common stock, value                       $ 1,500                
Catastrophe [Member] | EIDL Loan [Member]                                        
Loans [Line Items]                                        
Received economic injury disaster loan                                       $ 150
Subsidiaries [Member]                                        
Loans [Line Items]                                        
Credit facility   $ 1,500                                    
Credit line                       $ 900                
v3.24.3
Warrants (Details) - Series B Redeemable Preferred Stock [Member]
Aug. 24, 2016
$ / shares
shares
Warrants [Line Items]  
Purchase of warrants | shares 7,305
Exercise price | $ / shares $ 10.2672
v3.24.3
Commitments and Contingencies (Details) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Loss Contingencies [Line Items]    
Royalties to be paid, percentage 100.00%  
Grants received $ 14,300,000  
Interest amount 15,830  
Repaid grants 10,518,000  
Pay royalties $ 1,033,000 $ 1,062,000
v3.24.3
Shareholders’ Equity (Details) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Dec. 20, 2023
May 31, 2023
May 08, 2023
Aug. 31, 2023
Jul. 31, 2023
Feb. 28, 2023
Jan. 31, 2023
Feb. 28, 2023
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Jun. 05, 2024
Shareholders Equity [Line Items]                              
Total price (in Dollars)                           $ 50,000  
Common stock, shares issued         190,000                    
Common stock, par value (in Dollars per share)   $ 0.0001     $ 0.0001           $ 0.0001   $ 0.0001    
Exercise of the pre-funded warrant     970,187   754,670 754,670 754,670         970,187      
Pre-funded warrants         754,670                    
Warrants exercise price reduced (in Dollars per share)         $ 0.0001                    
Exercise price of pre-funded warrant (in Dollars per share)     $ 0.0001     $ 0.0755 $ 0.0755         $ 0.097      
Fair value of warrants (in Dollars)                         (1,658,000)  
Cash paid to underwriters (in Dollars)       $ 291,000                      
Common stock, shares issued   3,007,745                 6,254,664   6,254,664    
Warrant exercise price percentage       125.00%                      
Offering share price (in Dollars per share)   $ 1,475   $ 4,631.3000                      
Total gross amount (in Dollars)     $ 1,500,000                        
Warrants exercise price (in Dollars per share) $ 2                       $ 1.75    
Warrants to purchase common stock 999,670                   1,999,340 999,670 1,999,340    
Paid in cash to underwriter (in Dollars)   $ 129,000                          
Offering cost (in Dollars)   $ 230,000                          
Warrant exchange description                         Pursuant to the inducement agreement, the holder agreed to exercise for cash the 2 Years June Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.00 per share, in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “July Warrants”), for an exercise price of $1.75 at a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $250.    
Class of warrant or rights date 2 years                       2 years    
Warrant exerisable remaining term 2 years                       2 years    
Warrants to purchase (in Dollars)                         $ 50,000  
Underwriter Warrants [Member]                              
Shareholders Equity [Line Items]                              
Fair value of warrants (in Dollars)       $ 104,000                 $ 42,000    
Share-Based Payment Arrangement, Option [Member]                              
Shareholders Equity [Line Items]                              
Warrants exercise price (in Dollars per share)         $ 2.75               $ 2.75    
Investor [Member]                              
Shareholders Equity [Line Items]                              
Stock issued and sold to investor (in Dollars)         $ 3,500,000                    
H.C. Wainwright & Co., LLC [Member]                              
Shareholders Equity [Line Items]                              
Exercise price percentage   125.00%                     125.00%    
Issuance cost amount (in Dollars)                         $ 66,000    
Common Warrants [Member]                              
Shareholders Equity [Line Items]                              
Common stock, par value (in Dollars per share)                           $ 0.0001  
Warrants exercise price reduced (in Dollars per share)         $ 3.58               $ 1.18    
Purchase of warrants         944,670           1,271,187   1,271,187 944,670  
Fair value (in Dollars)         $ 1,972,000                    
Exercise price of warrant (in Dollars per share)                           $ 2.75  
Fair value of warrants (in Dollars)                         $ 314,000    
Warrants exercise price (in Dollars per share)                         $ 1.18    
Purchase of common shares                         69,977    
Additional Common Warrants [Member]                              
Shareholders Equity [Line Items]                              
Purchase of warrants                           55,000  
Warrant [Member]                              
Shareholders Equity [Line Items]                              
Purchase of warrants   88,983                          
Fair value of warrants (in Dollars)   $ 55,000                     $ 1,451,000    
Common stock, shares issued       66,127                      
Expected volatility   57.00%                     44.77%    
Risk-free rate   3.86%                     3.95%    
Contractual term   5 years 6 months                          
Share price (in Dollars per share)   $ 1.18                 $ 1.97   $ 1.97    
Offering cost (in Dollars)                     $ 2,999,000   $ 2,999,000    
Reduced exercise price (in Dollars)                         $ (3,437.5000)    
Warrant [Member] | Share-Based Payment Arrangement, Option [Member]                              
Shareholders Equity [Line Items]                              
Warrants exercise price (in Dollars per share)                         $ 2.75    
Warrants to purchase common stock                     999,670   999,670    
Warrant [Member] | H.C. Wainwright & Co., LLC [Member]                              
Shareholders Equity [Line Items]                              
Cash paid to underwriters (in Dollars)                         $ 331,000    
June Warrants [Member]                              
Shareholders Equity [Line Items]                              
Purchase of warrants                     1,999,340   1,999,340    
Warrants exercise price (in Dollars per share)                         $ 2    
Warrants to purchase common stock                     999,670   999,670    
Offering cost (in Dollars)                     $ 2,249,000   $ 2,249,000    
Class of warrant or rights date                         5 years 6 months    
Warrant exerisable remaining term 2 years                       2 years    
July Warrants [Member]                              
Shareholders Equity [Line Items]                              
Class of warrant or rights date                         2 years    
Warrant Inducement Agreement June 2024 [Member]                              
Shareholders Equity [Line Items]                              
Warrant exchange description                         Pursuant to the inducement agreement, the Holder agreed to exercise for cash the Existing Warrants to purchase an aggregate of 999,670 shares of the Company’s common stock at an exercise price of $2.75 per share in consideration of the Company’s agreement to issue new common stock purchase warrants, to purchase up to an aggregate of 1,999,340 shares of common stock (the “June Warrants”) for an exercise price of 2.00$ at a 1:1 exchange ratio.As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.    
Class of warrant or rights date                         5 years 6 months    
Offering Costs related to warrant inducement agreement [Member]                              
Shareholders Equity [Line Items]                              
Fair value of warrants (in Dollars)                         $ 27,000    
Risk-free rate                         3.86%    
Offering cost (in Dollars)                     $ 1,890,000   $ 1,890,000    
Warrant Inducement Agreement [Member]                              
Shareholders Equity [Line Items]                              
Cash paid to underwriters (in Dollars)                         $ 271,000    
Warrants exercise price (in Dollars per share)                         $ 2    
Exercise price percentage                         125.00%    
Expected volatility                         61.60%    
Contractual term                         2 years    
Share price (in Dollars per share)                     $ 1.65   $ 1.65    
Reduced exercise price (in Dollars)                         $ (2,500)    
Warrants to purchase (in Dollars)                         69,977    
Warrant Inducement Agreement [Member] | Warrant [Member]                              
Shareholders Equity [Line Items]                              
Offering cost (in Dollars)                     $ 1,429,000   1,429,000    
Warrant Inducement Agreement [Member] | July Warrants [Member]                              
Shareholders Equity [Line Items]                              
Fair value of warrants (in Dollars)                         $ 1,131,000    
At the Market Offering Agreement [Member]                              
Shareholders Equity [Line Items]                              
Common stock, shares issued                     227,939   227,939    
Shares of common stock                         3.4    
Gross proceeds (in Dollars)                         $ 328,000    
At the Market Offering Agreement [Member] | H.C. Wainwright & Co., LLC [Member]                              
Shareholders Equity [Line Items]                              
Percentage of gross sales price                         3.00%    
Common Stock [Member]                              
Shareholders Equity [Line Items]                              
Repurchase shares               7,920 7,920         7,920  
Total price (in Dollars)                   $ 50,000       [1]  
Common stock, shares issued                     227,939   227,939    
Common stock, par value (in Dollars per share)     $ 0.0001                        
Exercise of the pre-funded warrant     970,187                     754,670  
Common stock, shares issued     301,000                        
Warrants to purchase common stock                     999,670   999,670   999,670
Treasury Stock, Common [Member]                              
Shareholders Equity [Line Items]                              
Repurchase shares                         10,690    
[1] Represents an amount less than $1 thousand.
v3.24.3
Shareholders’ Equity (Details) - Schedule of Significant Inputs into the Black-Scholes Valuation Model
Sep. 30, 2024
Term [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement term 2 years
Term [Member] | 5.5 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement term 5 years 6 months
Term [Member] | 2 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement term 2 years
Expected volatility ]Member[  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 61.6
Expected volatility ]Member[ | 5.5 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 44.77
Expected volatility ]Member[ | 2 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 44.77
Risk-free rate [Member[  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 4.28
Risk-free rate [Member[ | 5.5 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 3.95
Risk-free rate [Member[ | 2 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 4.28
Stock price [Member[  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 1.65
Stock price [Member[ | 5.5 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 1.97
Stock price [Member[ | 2 Years June Warrants [Member]  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrant and rights measurement input 1.97
v3.24.3
Shareholders’ Equity (Details) - Schedule of Total Outstanding Warrant
Sep. 30, 2024
$ / shares
shares
Warrants May 2023 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 66,127
Warrants December 2023 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 1,360,170
Warrant June 2024 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 1,069,647
Warrants July 2024 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 2,069,317
Other Warrant [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 36,792
Warrant [Member]  
Class of Warrant or Right [Line Items]  
Number of warrant | shares 4,602,053
Minimum [Member] | Warrants May 2023 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 4.625
Period left in years 4 years 1 month 24 days
Minimum [Member] | Warrants December 2023 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 1.18
Period left in years 4 years 9 months
Minimum [Member] | Warrant June 2024 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 2
Period left in years 5 years 3 months
Minimum [Member] | Warrants July 2024 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 2.5
Period left in years 2 years
Minimum [Member] | Other Warrant [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 10.27
Period left in years 1 year 9 months
Maximum [Member] | Warrants May 2023 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 4.625
Period left in years 4 years 1 month 24 days
Maximum [Member] | Warrants December 2023 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 1.47
Period left in years 4 years 9 months
Maximum [Member] | Warrant June 2024 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 3.43
Period left in years 5 years 3 months
Maximum [Member] | Warrants July 2024 [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 1.75
Period left in years 2 years
Maximum [Member] | Other Warrant [Member]  
Class of Warrant or Right [Line Items]  
Exercise price $ 50
Period left in years 2 years 7 months 24 days
v3.24.3
Shareholders’ Equity (Details) - Schedule of Share Options, Granted to Employees, Directors, Under Option Plans - $ / shares
3 Months Ended 9 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Number of Options, Outstanding balance 87,764 72,945 65,380
Weighted- Average Exercise Price, Outstanding balance $ 3.63   $ 9.81
Weighted Average Remaining Contractual Life, Outstanding balance 4 years 1 month 9 days   3 years 4 months 24 days
Number of Options, Exercisable     60,799
Weighted- Average Exercise Price, Exercisable     $ 9.81
Weighted Average Remaining Contractual Life, Exercisable     2 years 8 months 12 days
Number of Options, Granted    
Weighted- Average Exercise Price, Granted    
Number of Options, Exercised     (21,225)
Weighted- Average Exercise Price, Exercised     $ 3.37
Number of Options, Forfeited     (1,159)
Weighted- Average Exercise Price, Forfeited     $ 16.5
v3.24.3
Shareholders’ Equity (Details) - Schedule of RSUs, Granted to Employees, Directors, Under Option Plans - RSUs [Member]
9 Months Ended
Sep. 30, 2024
$ / shares
shares
Schedule of RSUs, Granted to Employees, Directors, Under Option Plans [Line Items]  
Number of RSUs, RSUs outstanding at the beginning of the year | shares 71,280
Weighted- Average Grant Date Fair Value, RSUs outstanding at the beginning of the year | $ / shares $ 10.35
Number of RSUs, Granted during the year | shares
Weighted- Average Grant Date Fair Value, Granted during the year | $ / shares
Number of RSUs, Vested during the year | shares (28,228)
Weighted- Average Grant Date Fair Value, Vested during the year | $ / shares $ 3.79
Number of RSUs, Forfeited during the year | shares (6,798)
Weighted- Average Grant Date Fair Value, Forfeited during the year | $ / shares $ 6.35
Number of RSUs, RSUs outstanding at the end of the year | shares 36,254
Weighted- Average Grant Date Fair Value, end of the year | $ / shares $ 6.15
v3.24.3
Basic and Diluted Loss Per Share (Details) - $ / shares
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Basic and Diluted Loss per Share [Line Items]      
Diluted loss per share (in Dollars per share) $ 4,602,053 $ 1,047,589  
Outstanding options 65,380 72,945 87,764
Warrant [Member]      
Basic and Diluted Loss per Share [Line Items]      
Outstanding warrants 4,602,053    
Outstanding options 36,254    
Warrant [Member] | Restricted Stock Units (RSUs) [Member]      
Basic and Diluted Loss per Share [Line Items]      
Outstanding warrants 65,380 90,377  
v3.24.3
Basic and Diluted Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Shareholders - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:        
Net loss (in Dollars) $ (511) $ (867) $ (2,575) $ (4,355)
Denominator:        
Common shares outstanding used in computing net loss per share attributable to common shareholders 6,014,548 2,389,296 3,782,947 1,998,123
Pre-Funded warrants to purchase common shares 304,250 646,791 262,712
Repurchase of common stock (7,920) (6,600)
Weighted average number of shares used in computing basic net loss per share attributable to common shareholders 6,014,548 2,685,626 4,429,738 2,254,235
Weighted average number of shares used in computing diluted net loss per share attributable to common shareholders 6,014,548 2,685,626 4,429,738 2,254,235
Net loss per share attributable to common shareholders – basic (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
Net loss per share attributable to common shareholders – diluted (in Dollars per share) $ (0.09) $ (0.32) $ (0.59) $ (1.93)
v3.24.3
Revenues (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2024
USD ($)
Revenues [Abstract]  
Operating segment 1
Remaining performance obligation $ 437
v3.24.3
Revenues (Details) - Schedule of Revenues by Geographic Areas - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Schedule of Revenues by Geographic Areas [Line Items]        
Revenues $ 2,541 $ 845 $ 6,698 $ 4,589
North America [Member]        
Schedule of Revenues by Geographic Areas [Line Items]        
Revenues 1,854 454 5,316 1,863
Europe, the Middle East and Africa [Member]        
Schedule of Revenues by Geographic Areas [Line Items]        
Revenues 614 371 1,282 2,274
Asia Pacific [Member]        
Schedule of Revenues by Geographic Areas [Line Items]        
Revenues $ 73 $ 20 $ 100 $ 452
v3.24.3
Revenues (Details) - Schedule of Revenues from Contract Liability - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Schedule of Revenues from Contract Liability [Abstract]    
Opening balance $ 460 $ 648
Revenue recognized that was included in the contract liability balance at the beginning of the year (607) (544)
Additions 584 356
Remaining performance obligations $ 437 $ 460
v3.24.3
Revenues (Details) - Schedule of Revenues Recognized - Customer Concentration Risk [Member] - Revenue [Member] - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Customer A [Member]        
Schedule of Revenues Recognized [Line Items]        
Percentage revenues 45.00% 2.00% 18.00% 20.00%
Revenues net $ 1,143 $ 20 $ 1,205 $ 920
Customer B [Member]        
Schedule of Revenues Recognized [Line Items]        
Percentage revenues 2.00% 24.00% 34.00% 11.00%
Revenues net $ 51 $ 201 $ 2,227 $ 510
Customer C [Member]        
Schedule of Revenues Recognized [Line Items]        
Percentage revenues 10.00% 2.00% 6.00% 10.00%
Revenues net $ 254 $ 20 $ 401 $ 469
Customer D [Member]        
Schedule of Revenues Recognized [Line Items]        
Percentage revenues   10.00%   4.00%
Revenues net   $ 80   $ 171

Grafico Azioni Actelis Networks (NASDAQ:ASNS)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Actelis Networks
Grafico Azioni Actelis Networks (NASDAQ:ASNS)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Actelis Networks